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Summary 
Data obtained in our laboratory established FUBP1 (Fuse Binding Protein 1) as an 
important oncoprotein overexpressed in HCC (Hepatocellular Carcinoma) that 
induces tumor propagation through direct or indirect repression of cell cycle 
inhibitors and pro-apoptotic target genes. However, Prof. Kinzler’s laboratory 
(Ludwig Center for Cancer Genetics and Howard Hughes Medical Institutions, 
USA) found that inactivating mutations in the genes CIC and FUBP1 contribute to 
human oligodendroglioma. Their study enhanced our interest in investigating the 
expression levels of FUBP1 in different glioma cells. We detected low expression 
of FUBP1 in astrocytes and demonstrated elevated levels of FUBP1 in 
glioblastoma, the most common malignant brain tumor in humans. Among the 
challenges in the treatment of glioblastoma are the frequency of recurrence, the 
aggressiveness and the infiltrative behavior of the tumor. In contrast to 
oligodendroglioma, glioblastoma seem to require significant FUBP1 levels. 
The glioblastoma cell lines LNT229 and U87-MG were used to explore the 
oncogenic function of FUBP1 in glioblastoma, and further functional assays were 
performed. The results from the proliferation and apoptosis assays revealed less 
proliferation and more apoptosis in LNT229 FUBP1 knockdown cells, which co-
relates with results obtained with HCC cell lines. In contrast to LNT229, U87-MG 
cells showed more proliferation and less apoptosis upon FUBP1 knockdown. 
Interestingly, FUBP1-deficient U87-MG cells showed enhanced xenograft tumor 
growth. Affymetrix array results revealed a significant upregulation of pro-apoptotic 
genes in FUBP1 knockdown LNT229 cells in contrast to FUBP1 knockdown U87-
MG cells. In the latter, pro-proliferative and pro-angiogenic genes were significantly 
upregulated. qRT-PCR analysis showed a significant increase in TGFβ-1, MMP2 
and AKT in U87-MG FUBP1-deficient cells while these genes were downregulated 
in LNT229 FUBP1-deficient cells. Interestingly, the knockdown of MMP2 in U87-
MG cells led to a significant increase in FUBP1 protein levels. Further, APAF-1 
mRNA levels were investigated in LNT229 and U87-MG cells. To our surprise, 
APAF1 levels were high in FUBP1-deficient LNT229 cells compared to control 
LNT229 cells. However, we detected no change in APAF1 levels between control 
and FUBP1-deficient U87-MG cells. We speculate that different signaling 
pathways are activated in LNT229 and U87-MG cells upon FUBP1 knockdown. 
Therefore, we hypothesize that FUBP1 might fulfill a special important function as 
an oncogene in glioblastomas which might differ from its role in HCC.  
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Zusammenfassung 
Das Far Upstream Binding Protein 1 (FUBP1) wurde in unserer Arbeitsgruppe als 
ein wichtiges Onkoprotein im Hepatozellulären Karzinom (HCC) identifiziert. Es 
konnte gezeigt werden, dass es in über 90% aller HCCs überexprimiert wird und 
die Tumorentwicklung durch direkte und indirekte Regulierung von Zellzyklus-
Inhibitoren sowie pro-apoptotischen Zielgenen positiv beeinflusst. Die Gruppe von  
Prof. Kinzler (Ludwig Center for Cancer Genetics and Howard Hughes Medical 
Institutions, USA) hat interessanteweise herausgefunden, dass die Gene CIC und 
FUBP1 in Oligodendrogliomen durch geringe Mutationen inaktiviert sindwasauf 
eine Tumor-suppressor-function von FUBP1 in dieser Tumor-entität hinweisen 
könnte. Bei der Untersuchung von Gliomzellen konnten wir eine geringe 
Expression von FUBP1 in Astrozyten feststellen und ein hohes FUBP1-Level in 
Glioblastomzellen. Das Glioblastom ist ein sehr aggressiver Hirntumor mit einer 
sehr hohen Rückfallquote, der vor allem durch sein infiltratives Wachstum 
charakterisiert wird. Im Vergleich zu dem weniger aggressiven Oligodendrogliom 
scheint im Glioblastom eine höhre FUBP1-Expression benötigt zu werden. 
In dieser Arbeit sollte die onkogene Funktion von FUBP1 in den beiden 
Glioblastom-Zelllinien LNT229 und U87-MG untersucht werden. Proliferations- 
und Apoptose-Analysen in LNT229 FUBP1-knockdown Zellen zeigten eine 
verringerte Proliferations- und eine erhöhte Apoptoserate, was mit den 
Ergebnissen im HCC korreliert. Im Gegensatz dazu wurde in den U87-MG Zellen 
eine erhöhte Proliferationsrate und eine erhöhte Apoptoseresistenz nach der 
Herrunter-Regulation von FUBP1 beobachtet. Zusätzlich zeigte sich in einem 
Maus-Xenograft Experiment mit FUBP1-defizienten U87-MG Zellen ein stärkeres 
Tumorwachstum im Vergleich zu U87-MG Kontrollzellen mit normaler FUBP1-
Expression. Eine genomweite Expressionsanalyse der Zellen ergab, dass durch 
die Inhibierung von FUBP1 in den LNT229 Zellen pro-apoptotische Gene 
hochreguliert werden, während bei den FUBP1-defizienten U87-MG Zellen pro-
proliferative und pro-angiogenetische Gene signifikant erhöht waren. Die mRNA 
Analyse mittels qRT-PCR zeigte einen signifikanten Anstieg an TGFβ-1, MMP2 
und AKT in U87-MG FUBP1-defizienten Zellen, während diese Gene in LNT229 
FUBP1-defizienten Zellen herunterreguliert waren. Des Weiteren konnte der 
Anstieg von FUBP1 nach Herunterregulation von MMP2 in U87-MG Zellen gezeigt 
werden. Zusätzlich wurde beobachtet, dass das pro-apoptotische Adapterprotein 
APAF-1 in FUBP1-defizienten LNT229 Zellen im Vergleich zu LNT229-
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Kontrollzellen hoch expremiert wurde, während es keinen Unterschied zwischen 
FUBP1-defizienten U87-MG und Kontrollzellen gab. 
Demzufolge nehmen wir an, dass die Inhibierung von FUBP1 in diesen beiden 
Zelllinien zur Aktivierung unterschiedlicher Signalwege führt, und dass FUBP1 in 
Gehirntumoren eine Rolle spielen könnte, die sich von der im HCC unterscheidet
Introduction 
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1.1 Far Upstream Element (FUSE) Binding Protein 1 
The far upstream element (FUSE) binding protein 1 (FUBP1) was originally found 
to bind to the approx. 40 base pair long DNA sequence motif FUSE, which is 
located for example 1.5 kb upstream of the transcriptional start site of the c-myc 
p2 promoter. Experiments revealed that the transcriptional regulator FUBP1 
enhances c-myc promoter activity (Duncan, Bazar et al. 1994). Furthermore, the 
activity of the c-myc promoter was reduced upon mutations in the FUSE element 
(Avigan, Strober et al. 1990). 
1.1.1 FUBP family members and their domain structure 
The human FUBP1 gene encodes a 644-amino acid protein, with a molecular mass 
of 67.5 kDa, which consist of three domains (Figure 1): the N-terminal repression 
domain (1-106 aa), the C-terminal transactivation domain (with tyrosin-rich motifs) 
and the central DNA binding domain (107-447 aa), built of four conserved K-
homology (KH) motifs (Duncan, Bazar et al. 1994, Davis-Smyth, Duncan et al. 
1996). The KH motifs were first identified within the heterogenous nuclear 
ribonucleoprotein K (hnRNPK) (Valverde, Edwards et al. 2008), and they assist in 
the binding to single stranded DNA. In an inactive state, the C-terminal 
transactivation domain of FUBP1 is repressed by the N-terminal domain (Davis-
Smyth, Duncan et al. 1996). The mechanism of activation, leading to 
conformational changes of FUBP1 and thereby dissolving the enclosed 
conformation of the inactive protein, is not well studied (Zhang and Chen 2013). 
However, in the active state, the C-terminal transactivation domain is responsible 
for the function of FUBP1 as a transcriptional regulator (Davis-Smyth, Duncan et 
al. 1996). The interaction between FUBP1 and the transcription factor TFIIH 
(consisting of 9 different proteins) is aided by the three tyrosine rich-motifs of the 
C-terminal transactivation domain (Liu, Akoulitchev et al. 2001). Three nuclear 
localization signals (NLS) ensure the nuclear localization of the protein.     
  
 
1. Introduction 
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Figure 1: Structure of the FUBP1 protein 
FUBP1 is structured into three domains: an N-terminal repression domain, a central single stranded 
nucleotide binding domain (consisting of four KH motifs) and a C-terminal transactivation domain 
(containing three tyrosine-rich motifs) (Michelotti, Michelotti et al. 1996).  
 
Two genes (FUBP2 and FUBP3) with high similarity to FUBP1 were identified. 
FUBP2 is also known as K-homology splicing regulator protein (KHSRP). The 
overall amino acid sequence of FUBP1 shows a homology of 63.6% with FUBP2 
and 56.6% with FUBP3. Moreover, the highest conservation (~80%) is observed 
in the central binding domain (Davis-Smyth, Duncan et al. 1996). Nevertheless, 
FUBP2 and FUBP3 are localized on different chromosomes (Chr. 19 and 9, 
respectively) compared to FUBP1 (Bouchireb and Clark 1999). The role of FUBP2 
in stabilization, degradation, splicing and trafficking of mRNA is well studied 
(Gherzi, Lee et al. 2004). The activation potential of the C-terminal transactivation 
domain is strongest in FUBP3, moderate in FUBP1 and weakest in FUBP2. The 
functional differences in the N-terminal repression domain influence the interaction 
of FUBP1/2/3 with the antagonistic FUBP-interacting repressor (FIR). FUBP3 is 
not capable to interact with FIR, in contrast to FUBP1 and FUBP2 (Chung, Liu et 
al. 2006). 
 
1.1.2 Functions of FUBP1 
FUBP1 is known to transcriptionally activate the c-myc-promoter. c-Myc is involved 
in cell cycle progression and apoptosis, subsequently implying a potential role of 
FUBP1 in the above mentioned processes. Different studies state and have 
confirmed the potential role of FUBP1 in diverse cell fate decisions. Upon FUBP1 
knockdown, decreased cell proliferation in U2OS and Saos-2 osteosarcoma cell 
lines (He, Weber et al. 2000) was observed due to reduced c-myc expression. 
Furthermore, upon induction of differentiation in HL-60 and U937 leukemia cells, 
FUBP1 levels were decreased and c-Myc expression vanished (Avigan, Strober et 
al. 1990). 
Introduction 
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All FUBP family members possess the KH domains, which are important for the 
binding of single stranded DNA or RNA (Valverde, Edwards et al. 2008). Although 
the underlying mechanism is not well studied, FUBP1 seems to be involved in the 
regulation of neuronal differentiation, viral replication, cell growth and cell cycle 
progression. It was also observed that FUBP1 influences the hematopoietic stem 
cell self-renewal during definitive hematopoiesis, most certainly by regulating 
cellular proliferation and apoptosis (Katharina Gerlach, AG Zörnig; un-published 
data).  
 
1.1.3 Molecular function of FUBP1 
“Traditional” transcription factors commonly bind to double-stranded rather than 
single-stranded DNA. The basal transcription of the c-myc gene is hardly 
influenced by FUBP1; instead, FUBP1 promotes the maximum level of c-myc 
transcription, as described in the following passage. Upon serum addition, basal 
transcription of c-myc starts, leading to torsional stress and unwinding of DNA. Due 
to melting of the double-stranded DNA, the AT-rich FUSE element is exposed in 
its single stranded conformation (Duncan, Bazar et al. 1994), thereby enabling the 
binding of FUBP1. However, FUBP1 substitutes FUBP3 by an unknown 
mechanism, and c-Myc mRNA expression increase exponentially. FUBP1 causes 
the looping of DNA in the promoter region and interacts with the common 
transcription factor TFIIH, thereby enhancing its helicase activity. TFIIH is 
important for promoter clearance by RNA Polymerase II (Maxon, Goodrich et al. 
1994), and upon FUBP1 binding increases its activity on the c-myc promoter, 
allowing full scale c-myc transcription (Michelotti, Michelotti et al. 1996). Two hours 
after serum addition, a maximum of c-myc transcription is observed. Upon binding 
of the antagonist FIR, a triple complex consisting of FUSE, FIR and FUBP1 is 
formed. Eventually, FIR replaces FUBP1, and c-myc peak expression is reduced 
to basal levels. The important interplay between FUBP1, FUSE, FIR and TFIIH 
(Figure 2), as well as TFIIH, allows the precise control of the c-myc promoter and 
the exponential increase and decrease of c-myc mRNA expression in the G1 
phase of the cell cycle. 
Introduction 
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Figure 2: Schematic overview of the interplay between FUSE, FUBP1 and FIR during regulation of 
c-myc transcription 
Basal transcription at the c-myc promotor leads to negative supercoiling of the DNA upstream of the 
promoter region. Melted FUSE sequence facilitates the binding of FUBP1 protein, which mediates a 
steep increase in c-myc transcription. Eventually, binding of FIR to FUSE and FUBP1 leads to 
termination of c-myc expression back to basal levels (Hsiao, Nath et al. 2010).  
 
 
1.1.4 FUBP1 as a Cancer Biomarker 
Because FUBP1 upregulates c-myc mRNA expression and facilitates pro-
oncogenic functions, its expression is increased in many cancer types (see Table 
1, (Zhang and Chen 2013)). As another suggested mode of oncogenic action, 
FUBP1 promotes the replication of HCV, a virus which causes hepatocellular 
carcinoma (Zhang, Harris et al. 2008). 
In colorectal cancer patients, a splicing variant of FIR was found, which lacked the 
N-terminus and was therefore unable to inhibit FUBP1 activity. This splicing variant 
exhibits dominant negative effects compared to functional wildtype FIR and is only 
found in colorectal cancer tissue, indicating a potential role in colorectal 
carcinogenesis (Matsushita, Tomonaga et al. 2006, Matsushita, Kajiwara et al. 
2009).  
Studies in clear cell renal cell carcinoma (ccRCC) showed a correlation between 
elevated FUBP1 and c-myc levels, indicating that FUBP1 facilitates oncogenic 
functions (Weber, Kristiansen et al. 2008). The high/over expression of FUBP1 in 
cancer cells compared to normal tissue suggest FUBP1 as a potent onco-protien 
and cancer biomarker.  
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Table 1: FUBP1 expression in different cancers entities (Zhang and Chen 2013) 
Malignancy Alterations   
Downstream 
Target 
Reference 
Oligodendrioglioma FUBP1 
mutational 
inactivation 
  NA (Bettegowda, 
Agrawal et al. 2011) 
Non-small lung 
cancer 
FUBP1 ↑   Stathmin 1 ↑ (Singer, Malz et al. 
2009) 
Breast FUBP1 ↑   NA  (Lasserre, Fack et 
al. 2009, Xu, Yan et 
al. 2010) 
Clear cell renal 
cancer 
FUBP1 ↑   c-myc ↑ (Weber, Kristiansen 
et al. 2008) 
Liver FUBP1 ↑   p21 ↑, p15 ↑, 
Cyclin D2 ↑ 
(Zubaidah, Tan et 
al. 2008, 
Rabenhorst, 
Beinoraviciute-
Kellner et al. 2009) 
Liver FUBP1 ↑   Stathmin 1 ↑ (Zubaidah, Tan et 
al. 2008, Malz, 
Weber et al. 2009) 
Bladder FUBP1 ↑   NA (Weber, Kristiansen 
et al. 2008) 
Prostate FUBP1 ↑   NA (Weber, Kristiansen 
et al. 2008) 
Colon FIR 
truncation 
  c-myc ↑ (Matsushita, 
Tomonaga et al. 
2006, Matsushita, 
Kajiwara et al. 
2009) 
NA: not available 
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1.2 Role of FUBP1 in Gliomas 
Gliomas denote the most frequent cancer of the central nervous system (CNS), 
accounting for about 80 % of all malignant primary brain and CNS tumors (Hinsdale 
2011). Gliomas are defined as tumors derived from glial cells and include tumors 
of astrocytic, oligodendrial, ependymal, or mixed origin. Based on histological 
appearance, the World Health Organization (WHO) classifies the different types of 
gliomas into prognostic grades ranging from I to IV (Louis, Ohgaki et al. 2007). The 
most malignant astrocytic glioma, glioblastoma multiforme (WHO grade IV), 
constitutes more than 50 % of all gliomas and is the most common malignant 
primary brain tumor (Hinsdale 2011). Even though glioblastoma multiforme is a 
quite rare tumor with a global incidence rate of only 3.17 per 100,000 (Hinsdale 
2010), it significantly impacts the life of the affected patients due to its poor 
prognosis with a median survival time of only 12-15 months from the time of 
diagnosis (Stupp, Mason et al. 2005). 
 
Figure 3: De novo vs Secondary GBM genetic pathways. 
A classification of brain tumors that is based on their cell-of-origin according to WHO grade. The 
molecular and genetic changes along the percentages of their possible occurrence for the onset of 
the disease is being described (Ohgaki and Kleihues 2007).  
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1.2.1 Astrocytomas 
Diffuse astrocytomas are comprised of tumor cells with histological characteristics 
of astrocytes and they present the most common type of all gliomas. They account 
for 60% of all primary brain tumors. The subtypes according to malignancy are 
diffuse astrocytomas (AII, WHO grade II), anaplastic astrocytomas (AA, WHO 
grade III) and glioblastoma multiforme (GBM, WHO grade IV), whereby 
glioblastomas are the most common astrocytoma subtype (Figure 3) (Louis, 
Ohgaki et al. 2007). Diagnosis of astrocytomas is based upon histological findings 
of fibrillary or gemistocytic neoplastic astrocytes with specific nuclear 
characteristics, surrounded by a loosely structured tumor matrix. The astrocytic 
nucleus is elongated and often has a distinct nucleolus. Astrocytes have more 
extensive cellular processes than oligodendrocytes. In addition, increased 
cellularity and the presence of significant mitotic activity upgrades the tumor to an 
anaplastic astrocytoma grade III. Anaplastic astrocytomas can progress from a 
diffuse astrocytoma grade II but may also arise de novo, i.e. without a less 
malignant precursor lesion. Additional features such as cellular pleomorphism, 
vascular thrombosis, microvascular proliferation and/or necrosis are diagnostic for 
a glioblastoma, grade IV. Most glioblastomas (>90%) arise rapidly de novo and are 
called primary glioblastomas. Secondary glioblastomas develop from a previously 
diagnosed diffuse astrocytoma grade II or anaplastic astrocytoma grade III. It is 
believed that the progression from a low grade to a high-grade tumor is associated 
with cumulative genetic alterations. 
 
1.2.2 Oligodendroglioma 
Oligodendrogliomas are composed of tumor cells with histological characteristics 
of oligodendrocytes. The two subtypes described in the literature are 
oligodendroglioma (OII, WHO grade II) and anaplastic oligodendroglioma (AO, 
WHO grade III). Mostly middle-aged adults are diagnosed with oligodendroglioma. 
In general, oligodendroglioma are slowly dividing, with relatively long survival times 
for the patients. Oligodendrogliomas classified as grade II are well differentiated 
and slowly dividing rounded cells consisting of homogenous slightly enlarged 
nuclei with increased chromatin density.  
 
Recently, novel somatic mutations have been identified in oligodendroglioma 
which represents the second most common primary neuro-epithelial human brain 
Introduction 
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tumor (Bettegowda, Agrawal et al. 2011). Several mutations are located in the 
FUBP1 gene and have been detected in 10-15% of all oligodendroglioma patients. 
In contrast to other mutations associated with oligodendroglioma such as IDH1, no 
hot-spot codon for FUBP1 mutations has been identified (Hartmann, Meyer et al. 
2009, Sahm, Koelsche et al. 2012). Genetic analysis revealed that all the mutations 
result in inactivation of the encoded protein, as the mutations result in either 
deletions or nonsense sequences (Bettegowda, Agrawal et al. 2011). However, 
the function of the FUBP1 protein in the normal and neoplastic human brain is 
poorly understood.  
 
1.2.3 Glioblastoma 
Glioblastoma (GBM) is the most common primary brain tumor and accounts for 
over fifty-one percent of all gliomas (Adamson, Kanu et al. 2009). Over 13,000 
deaths are recognised to gliomas annually, and approximately 18,000 new cases 
are diagnosed each year (Schwartzbaum, Fisher et al. 2006). As with many types 
of cancer, increasing age correlates with incidence; the average age of incidence 
of primary GBM is 62 years (Adamson, Kanu et al. 2009). GBM rarely affects 
children and only accounts for 8.8 percent of childhood brain tumors. Glioblastoma 
occurs in both men and women, however, primary GBM occurs more frequently in 
males while secondary GBM occurs more frequently in females (Schwartzbaum, 
Fisher et al. 2006). Although there are several treatments available for GBM 
including surgical resection, chemotherapy, and radiation, prognosis remains 
depressing. The average survival time following diagnosis of GBM patients is only 
14 months (adapted from American Brain Tumor Association) and the five-year 
survival rate of GBM is only ten percent. For comparison, another aggressive 
cancer, small cell lung carcinoma, has a median survival of twenty months and a 
five-year survival of twenty percent (adapted from National Cancer Institute). 
Current research in GBM concentrates on the development of new, targeted 
therapies for potential cure. As with all cancers, assessing possible risk factors 
remains a major focus of disease prevention. 
The World Health Organization (WHO) characterizes GBM as a grade IV tumor 
(Kelly, Kirkwood et al. 1984). GBM can present as either a primary or a secondary 
tumor, when the primary GBM has spread to another part of the brain. Primary 
tumors are more aggressive with lower survival rates than secondary tumors 
(American Brain Tumor Association). 
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Common pathologic characteristics of GBM include hyper-chromatic nuclei and the 
presence of necrotic tissue (Adamson, Kanu et al. 2009). Diffuse margins and 
microvascular proliferation allow GBMs to easily grow and metastasize. Tumors 
with diffuse margins more readily invade surrounding cerebral tissue which makes 
complete surgical resection difficult.  
 
The pathology of GBM is intrinsically linked to the molecular basis of this deadly 
disease. Many different molecular pathway mutations and genetic abnormalities 
can lead to gliomagenesis. The combination of several different onco-genomic 
events contributes to GBM development and therefore, the exact molecular cause 
of GBM is difficult to decode. The most common and frequent mutations and 
molecular causes of GBM are listed in Table 2. 
 
Table 2: Molecular causes and genetic changes for GBM occurrence (Kanu, Hughes et al. 2009). 
 
Molecular causes of GBM 
CAUSE    % INCIDANCE 
Deletion of chromosome 10 70% 
EGFR amplification 40%-60% 
P16INK4a deletion 30% 
P14ARF mutation 30% 
P53 mutation 30% 
PTEN mutation 25% 
RB1 methylated 15% 
MGMT methylated 36% 
 
 
Standard treatment for GBM patients includes surgical resection, chemotherapy, 
and radiation therapy. Surgical resection is performed with the intent for a complete 
removal of the GBM tumor. If a complete resection is impossible due to the location 
of the tumor, a partial resection may be performed; however, partial resection is 
associated with significantly lower survival rates. While there are many different 
chemotherapeutic agents available for the treatment of GBM, the current standard 
chemotherapy used is Temozolomide, or Temodar. Temozolomide is an oral 
alkylating agent, and inhibits DNA repair mechanisms in tumor cells (American 
Brain Tumor Association). 
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1.3 Extracellular matrix proteins  
The extracellular matrix (ECM) is the non-cellular component present in all tissues 
and organs, and provides essential support for the cellular constituents. 
Additionally, it also initiates crucial biochemical and biomechanical help which is 
required for tissue morphogenesis, differentiation and homeostasis (Jarvelainen, 
Sainio et al. 2009). Fundamentally, the ECM is composed of water, proteins and 
polysaccharides, each tissue has an ECM with a unique composition and topology 
that is generated during tissue development through a dynamic and reciprocal, 
biochemical and biophysical exchange between the various cellular components 
(e.g. epithelial, fibroblast, adipocyte, endothelial elements) and the evolving 
cellular and protein microenvironment. Cell adhesion to the ECM is mediated by 
ECM receptors, such as integrins, discoidin domain receptors and syndecans 
(Leitinger and Hohenester 2007, Harburger and Calderwood 2009). Adhesion 
mediates cytoskeletal coupling to the ECM and is involved in cell migration through 
the ECM (Schmidt and Friedl 2010).  
The ECM is composed of two main classes of macromolecules: proteoglycans 
(PGs) and fibrous proteins (Table 3). The main fibrous ECM proteins are collagens, 
elastins, fibronectins and laminins (Hoglund, Odelius et al. 2007). PGs have a wide 
variety of functions that reflect their unique buffering, hydration, binding and force-
resistance properties. 
Collagen is the most abundant fibrous protein within the interstitial ECM and 
constitutes up to 30% of the total protein mass of a multicellular animal. Collagens, 
which constitute the main structural element of the ECM, provide tensile strength, 
regulate cell adhesion, support chemotaxis and migration, and direct tissue 
development (Rozario and DeSimone 2010). 
Fibronectin (FN) is intimately involved in directing the organization of the interstitial 
ECM and, additionally, has a crucial role in mediating cell attachment and function. 
FN is also important for cell migration during development and has been implicated 
in cardiovascular disease and tumor metastasis (Rozario and DeSimone 2010, 
Tsang, Cheung et al. 2010).  
Matrix metalloproteinases (MMPs) are a large family of calcium-dependent zinc-
containing endopeptidases, which are responsible for the tissue remodeling and 
degradation of the extracellular matrix (ECM), including collagens, elastins, gelatin, 
matrix glycoproteins, and proteoglycan. MMPs are usually minimally expressed in 
normal physiological conditions and thus homeostasis is maintained. Over-
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expression of MMPs results in an imbalance between the activity of MMPs and 
TIMPs that can lead to a variety of pathological disorders (Aranapakam, Grosu et 
al. 2003, Venkatesan, Davis et al. 2004, Raspollini, Castiglione et al. 2005). MMPs 
have now been considered as a promising target for cancer therapy and a large 
number of synthetic and natural MMP inhibitors (MMPIs) have been identified as 
cytostatic and anti-angiogenic agents, and have begun to undergo clinical trials in 
view of their specific implication in malignant tissues. 
There are 25 known MMP genes in humans, and many of these are involved in 
cancer (Rao 2003). MMP expression is induced by cytokines, growth factors, tumor 
promoters, physical stress, oncogenic transformation, and cell-matrix and cell-cell 
interaction (Rao 2003). They are regulated in a variety of ways including gene 
expression, pro-enzyme activation, and inhibition through specific tissue inhibitors 
(TIMPs) (Brew, Dinakarpandian et al. 2000). MMPs are responsible for tumor 
invasion by degrading ECM proteins and releasing the growth factors to activate 
signal transduction cascades which promote migration (McCawley and Matrisian 
2001). MMP-2 and MMP-9 are predominantly involved in glioblastoma, and their 
mRNA and protein expression levels are higher in GBM patient biopsy tissue (Rao, 
Steck et al. 1993). Both of these MMPs are involved in GBM proliferation and 
migration through the activation of transforming growth factor beta- 1 (TGFβ-1). 
MMP-9 and MMP-2 promote GBM invasion in vitro and in xenograft models 
(McCawley and Matrisian 2001, Bellail, Hunter et al. 2004) and their inhibition 
dramatically reduces the invasive phenotype. 
 
Figure 4: Schematic representation of MMPs and their role in proliferation and migration of 
the tumor cells. 
The proteolytic degradation of the vascular basement membrane (VBM) is mediated by proteases, 
such as the matrix metalloproteases (MMPs), secreted by tumor and stromal cells. MMPs play an 
important role in human brain tumor invasion, migration and proliferation (Uhm, Dooley et al. 1997).  
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The developing fetal brain shows characteristics similar to that of the GBM, defined 
by elevated levels of fibrous ECM proteins. This is in contrast to the mature adult 
brain, which shows significantly lower expression of the same ECM proteins 
(Ruoslahti 1996). The fetal brain ECM contains elevated levels of the fibrous 
proteins, fibronectin, laminin, vitronectin and collagen (Mahesparan, Read et al. 
2003). The most abundant brain protein hyaluronan (HA) has also been shown to 
be elevated in the matrices of gliomas, similar to what is seen for the embryonic 
brain matrix (Ulrich, de Juan Pardo et al. 2009).  
Table 3: Expression of ECM proteins/molecules in normal brain and gliomas (Delpech, Maingonnat 
et al. 1993, Tysnes, Mahesparan et al. 1999).   
Molecules Abundance Function 
 Normal Brain Glioma  
Hyaluronic Acid (HA) 
Proteoglycan (PG) 
↑ 
↑ 
↑↑↑ 
↑↑↑ 
HA: space filling molecule, 
regulates cell 
proliferation, adhesion 
and motility. 
PG: HA binding proteins 
Fibrous Proteins 
 Vitronectin 
 Fibronectin 
 Laminin 
 Collagen IV 
Found in trace 
amounts along 
brain 
vasculature 
and basement 
membrane.  
 
↑↑↑ 
↑↑↑ 
↑↑↑ 
↑↑↑ 
Fibrous Proteins: 
structural elements of the 
connective tissue in the 
basement membrane of 
blood vessels of the 
normal brain and gliomas, 
in high grade gliomas they 
are also expressed and 
secreted by glioma cells. 
Matrix 
metalloproteinase 
(MMPs) 
↑ ↑↑↑ MMPs: Molecules that aid 
in the breakdown of the 
basement membrane 
during the ECM 
remodelling; MMP2, 
MMP9 
 
1.4 MicroRNA synthesis and functions   
MicroRNAs (miRNAs) are 20–22 nucleotides long noncoding RNAs that are 
important regulators of gene expression and were first described in 1993 (Lee, 
Feinbaum et al. 1993). MiRNAs play an important role in diverse cellular processes 
including development, immunity, cell-cycle control, metabolism, viral or bacterial 
disease, stem-cell differentiation, and oncogenesis (Ambros 2004, Bala, Marcos 
et al. 2009). In general, miRNAs are transcribed from RNA polymerase II or III in 
the nucleus and transported to the cytoplasm, where they are processed into 
mature miRNAs (Bartel 2009). Mature miRNAs can target hundreds of genes by 
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either binding to the 3’ or 5’ untranslated (UTR) region of mRNA (Bartel 2009). Pri-
miRNAs are cleaved into precursor miRNAs (pre-miRNAs) of about 50-150 
nucleotides by Drosha, an endoribonuclease III (RNAse III), and its cofactor RNA-
binding protein pasha (DGCR8). These pre-miRNAs are then exported to the 
cytoplasm by exportin 5. This is further excised to double-stranded duplexes of 
20–23 nucleotides by Dicer, an RNAse III enzyme. The miRNA duplex later 
separates into single-stranded mature miRNA, and incorporates into the RNA-
induced silencing complex (RISC), which is composed of Argonaute proteins. This 
complex further binds to the 3′-untranslated region (3′-UTR) of its target transcript 
and negatively regulates protein translation by a mechanism that depends on the 
complementarity between the miRNA and target messenger RNA. Partial 
complementarity results in translational repression, while complete 
complementarity triggers mRNA degradation (Figure 5). 
 
 
 
 
Figure 5: Schematic representation of Micro-RNA Biogenesis.  
In the nucleus, miRNAs are transcribed by Pol II. Pri-miRNAs are cleaved by Drosha and Pasha to 
pre-miRNAs that are exported to the cytoplasm by exportin 5. In the cytoplasam, pre-miRNAs are 
excised from a double-stranded miRNA: miRNA* duplex of 20-23 nucleotides by Dicer. The miRNA 
duplex unwinds to single-stranded mature miRNA and is incorporated into the RISC complex, which 
is composed of Argonaute proteins. The miRNA/RISC complex binds to the 3’-UTR of target cellular 
gene and negatively regulates gene expression. Perfect complementarity triggers mRNA 
degradation, while partial complementarity results in translational repression (Law and Wong 2011).   
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Studies suggest that miRNAs not only target mRNAs but are also capable of 
modulating transcription and methylation processes (Sinkkonen, Hugenschmidt et 
al. 2008, Sato, Tsuchiya et al. 2011). An important feature of miRNAs is that a 
single miRNA can regulate multiple target mRNAs. This property of miRNAs 
enables them to exert a wide control on a network of genes. Previous studies state 
that overexpression of a single miRNA can downregulate over 100 mRNAs (Lim, 
Lau et al. 2005). Therefore, it is not surprising that miRNAs are involved in diverse 
physiological and developmental processes. In a short time, miRNA research has 
received tremendous attention due to the fine-tuning roles of miRNAs in most 
biological pathways. Moreover, disease-specific tissue miRNA signatures have 
been identified in various diseases such as hepatocellular carcinoma (HCC), 
hepatitis C virus (HCV), hepatitis B virus (HBV), cardiac disease, neuro-
inflammation, rheumatic arthritis (RA), and various cancers (Budhu, Jia et al. 2008, 
Bala, Marcos et al. 2009, Maes, Chertkow et al. 2009, Nakasa, Nagata et al. 2011, 
Qu, Zhang et al. 2011). 
 
1.4.1 Role of miRNAs in HCC 
Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the 
third-leading cause of cancer-related death in the world (Forner, Llovet et al. 2012). 
The frequency of HCC is increasing in many parts of the world. The overall survival 
rate is 5–9% from the time of clinical diagnosis of HCC, and the prognosis is largely 
caused by late detection of the tumors (Poon and Fan 2004, Schwartz, Roayaie et 
al. 2007). Although the 5-year survival is better for patients who undergo curative 
resection if the tumor is detected early, these patients still have a high rate of 
recurrence (Yuen, Cheng et al. 2000, Fukuda, Itamoto et al. 2005). Hepato-
carcinogenesis is closely associated with chronic hepatitis B virus (HBV) and 
hepatitis C virus (HCV) infections (Yu and Chen 1994, Hung, Chen et al. 2013). 
More than 90% of HCC cases develop in chronically inflamed liver as a result of 
viral hepatitis and alcohol abuse and in increasing incidence in patients with non-
alcoholic fatty liver disease (Welzel, Graubard et al. 2011). Still the underlying 
molecular pathogenesis is not completely understood. 
 
HCC is pathologically and clinically a heterogeneous disease. The prognosis 
depends on the aggressiveness of the HCC and residual liver function (Bruix, 
Sherman et al. 2011). The progression of HCC is thought to involve the 
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deregulation of genes that are critical to cellular processes such as cell cycle 
control, cell growth, apoptosis, and cell migration and spreading. Previous studies 
have focused on investigating the genes and proteins essential for the 
development of HCC (Aravalli, Steer et al. 2008, Huang and He 2011). Recent 
reports identify microRNAs that are implicated in HCC development and 
progression. Various miRNAs were deregulated or aberrantly expressed in 
human HCC (Table 4) (Otsuka, Kishikawa et al. 2014). In most cases, HCC 
originates on a background of cirrhosis, a chronic and diffuse hepatic disease 
that results from continuous liver injury and regeneration, due to different factors. 
Different etiologies of HCC play a role in the different miRNA expression profiles.  
 
Table 4: miRNAs regulated in HCC (Otsuka, Kishikawa et al. 2014).   
miRNAs Molecular 
alteration 
Targets Characteristics 
miR-10a Upregulated EphA4, 
CADM1 
EMT, metastasis  
miR-17-5p Upregulated p38 pathway Multiple tumor nodules, vein 
invasion, shortened overall 
survival 
 
miR-18a Upregulated ER1a Poor prognosis, poor 
differentiation, proliferation 
 
miR-18b Upregulated TIMP3 Cell growth; tumorigenesis; 
metastasis 
 
miR-21 Upregulated C/EBPb, RhoB, 
PDCD4, PTEN 
Drugresistance, metastasis  
miR-23a Upregulated PGC-1a,G6PC Gluconeogenesis  
miR-143 Upregulated FNDC3B Metastasis  
miR-155 Upregulated SOCS1, DKK1, 
APC, PTEN 
High recurrence and poor 
prognosis following OLT, 
proliferation, tumorigenesis 
 
miR-210 Upregulated VMP1, AIFM3 Metastasis; apoptosis; 
proliferation 
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let-7 
a,b,c,d,f,g 
Downregulated STAT3 Apoptosis, proliferation, 
earlyrecurrence 
 
miR-1 Downregulated ET1 Proliferation  
miR-7a Downregulated PIK3CD, 
Caspase-3, 
HMGA2, C-
myc, BCL-Xl 
Proliferation, apoptosis, 
tumorigenesis, metastasis 
 
miR-26a/b Downregulated IL-6, CyclinD2, 
E2 
Poor survival  
miR-
199a/b-3p 
Downregulated PAK4, c-Met, 
mTOR, DDR1, 
caveolin-2 
Reduced time to recurrence, 
poor overall survival and 
progression-free survival rates, 
proliferation, autophagy, 
metastasis 
 
miR-200a Downregulated HDAC4 Proliferation, metastasis  
 
miRNAs represent promising diagnostic markers of HCC. In fact, miRNAs are 
stable in human serum/plasma once they are released from cancer cells. Studies 
have shown that circulating miRNAs are resistant to RNAse activity and extreme 
pH and temperature (Chen, Ba et al. 2008, Mitchell, Parkin et al. 2008). However, 
even though a number of HCC-associated miRNAs have been identified, only few 
of them are validated to assist in diagnosis of HCC. Inhibiting or overexpressing 
miRNAs have been considered as novel strategy in cancer therapy for HCC. In 
fact, the discovery of miRNAs as an important player in the development and 
progression of HCC has implied that miRNAs can be used as therapeutic targets. 
The complexity of miRNA biology offers novel mechanisms of action for 
therapeutics but at the same time poses unique challenges for the development of 
therapeutic drugs. The therapeutic application of miRNAs involves two strategies. 
The first aims to inhibit oncogenic miRNAs by using miRNA antagonists, such as 
antimiRs, locked nucleic acids (LNAs) or antagomiRs (Krutzfeldt, Kuwajima et al. 
2007). MicroRNA antagonists are single-stranded RNA molecules, approximately 
21–23 nt long, that act through complementary base-pairing with miRNAs. To 
achieve effective pharmacological inhibition of disease-associated miRNAs, 
miRNA antagonists contain chemical modifications to enhance binding affinity, 
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confer nuclease resistance, and facilitate cellular uptake (Krutzfeldt, Kuwajima et 
al. 2007). 
The second strategy, miRNA replacement, involves the reintroduction of a tumor 
suppressor miRNA mimetic to restore a loss of function (Bader, Brown et al. 2010). 
miRNA mimetics represent an additional level of complexity compared with 
antimiRs. This strategy involves the risk to induce unwanted effects when novel 
miRNAs are introduced into a cell, but currently, in vivo evidence for toxicity 
induced by miRNA mimetics is still lacking. 
1.5 Aim of the project 
The aim of this thesis was to evaluate the oncogenic function of FUBP1 in 
glioblastoma.  
At the beginning of the study, it was known that FUBP1 is highly deregulated in 
several cancerous tissues. In our group, we could show that FUBP1 is strongly 
overexpressed in hepatocellular carcinoma compared to normal liver tissue. 
Furthermore, a stable knockdown of FUBP1 in the human HCC cell Hep3B led to 
impaired tumor growth in a xenograft transplantation model (Rabenhorst, 
Beinoraviciute-Kellner et al. 2009). Interestingly, when FUBP1 was overexpressed 
using adenovirus, a significant increase in FUBP1 mRNA levels was observed but 
protein levels failed to show an equivalent increase. So, I speculated about the 
involvement of miRNAs in regulating the expression level of FUBP1 in HCC cell 
lines.  
Our group detected low expression of FUBP1 in astrocytes and demonstrated 
elevated levels of FUBP1 in glioblastoma, the most common malignant brain tumor 
in humans. In addition, Prof. Kinzler’s group found that inactivating mutations in 
the genes CIC and FUBP1 contribute to human oligodendroglioma (Bettegowda, 
Agrawal et al. 2011). 
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Based on these findings, the goal of the projects was:  
(i) to investigate the role of FUBP1 in glioblastoma cell lines.  
(ii) to identify miRNAs which are regulated by FUBP1 in HCC cell lines.  
For this purpose, the following issues were addressed: 
1. The expression analysis of FUBP1 in different glioblastoma cell lines 
2. The functional role (apoptosis, proliferation, migration, invasion) of FUBP1 
in glioblastoma cell lines 
3. Studying the consequences of FUBP1 knockdown in glioblastoma cell lines 
in in vivo mouse model 
4. Identification of potential molecular candidates that could explain the 
differential role of FUBP1 in different glioblastoma cell lines 
5. Identifying miRNAs that are regulated by FUBP1 in HCC cell lines using 
miRNA microarrays 
6. Validating the identified miRNAs by luciferase assays
Materials and Methods 
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2.1 Materials 
2.1.1 Plasmid and shRNA constructs 
Table 5: List of plasmids used  
 
2.1.2 qRT-PCR Oligonucleotides 
Table 6: qRT-PCR oligonucleotides  
Name Gene Sequence (5'3') 
qRT PCR huTGFβ-1 for TGFβ-1  tggcgatacctcagcaacc 
qRT PCR huTGFβ-1 rev TGFβ-1  ctcgtggatccacttccag 
qRT PCR huGAPDH-for GAPDH aatggaaatcccatcaccatct 
qRT PCR huGAPDH-rev GAPDH cgccccacttgattttgg 
qRT PCR huMMP2-for MMP2 gcggcggtcacagctactt 
qRT PCR huMMP2-rev MMP2 cacgctcttcagactttggttct 
qRT PCR huMMP9-for MMP9 tggggggcaactcggc 
qRT PCR huMMP9-rev MMP9 ggaatgatctaagcccag 
qRT PCR huIGF-II-for IGF-II ccgtgcttccggacaact 
qRT PCR huMMP9-rev IGF-II ctgcttccaggtgtcatattgg 
 
 
 
 
2. Materials and Methods  
Plasmid name  Plasmid description   Reference  
pGIPZ  Ampicillin resistance; puromycin 
selectable marker; GFP marker to 
detect shRNA expression  
Open Biosystems, 
Huntsville  
pMD2.G  Expression plasmid for vesicular 
stomatitis virus glycoproteins (vsv-
g)  
Addgene Inc.,  
Cambridge, UK 
M. Grez, GSH, 
Frankfurt.  
pCMV-dR8.91  Encapsidation plasmid for 
lentivirus production  
Addgene Inc., 
Cambridge, UK. 
M.Grez, GSH, 
Frankfurt.  
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2.1.3 Competent E.coli strain  
Table 7: E.coli strains used for DNA cloning experiments  
Strain  Genotype  Manufacturer  
DH5α  supE44 lacU169 (80lacZM15) hsdR17 recA1 
endA1 gyrA96 thi-1 relA1  
Clontech Laboratories  
Inc., Mountain View,  
CA, USA  
One Shot®  
TOP10 
F-mcrAΔ (mrr-hsdRMS-mcrBC) φ80 
lacZΔM15ΔlacX74 recA1 araD139Δ(ara-
leu)7697 galU galK rpsL(StrR) endA1 nupG 
Invitrogen GmbH, 
Darmstadt 
 
2.1.4 Enzymes 
Table 8: Enzymes used for molecular biology methods 
Enzyme Concentration [U/ml-1] Manufacturer 
DNAse I 5,000000* Sigma Aldrich Chemie, 
Taufkirchen 
RNAse A 100 mg / ml-1 Roche, Mannheim 
Taq Polymerase 5,000 Invitrogen GmbH, 
Darmstadt 
T4 DNA Ligase  200,000 NEBiolab, Schwalbach 
Omniscript Reverse Transcriptase 4 Qiagen GmbH, Hilden 
*Was used in lyophilized form, concentration in [U/mg-1] 
 
2.1.5 Cell culture materials  
2.1.5.1 Cell culture disposables  
Name   Manufacturer 
6 well plates Corning  Sarstedt, Nümbrecht; Greiner, 
Frickenhausen 
24 well plates Corning Sarstedt, Nümbrecht; Greiner, Frickenhausen 
96 well plates Corning Sarstedt, Nümbrecht; Greiner, Frickenhausen 
Cover slips VWR Supplier Partnership, Langenfeld 
Culture dishes (10-15 cm) Greiner, Frickenhausen 
Object slides VWR Supplier Partnership, Langenfeld 
Pipettes (5, 10, 25 ml) BD Falcon, Heidelberg 
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Sterile filter (Millex-GP, 0.45 μm) Millipore, Eschborn 
Sterile syringes Codan, Lensahn 
T25 flasks Greiner, Frickenhausen 
   
T75 flasks Greiner, Frickenhausen 
 
2.1.5.2 Cell lines  
Table 9: Cell lines used for functional studies 
 Cell line  Description  Reference  
HEK 293 T  human epithelial kidney cells derived from 
the HEK-293 cell line, which was 
transformed with the SV40 “larg T”-antigen.  
ATCC (CRL-11268) 
Hep3B 
Human hepatocellular carcinoma cells, 
positive for HepB  viral DNA sequences, S1 
ATCC (HB-8064™) 
LNT229 
Human glioblastoma cell line 
ATCC (CRL-2611TM) 
U-87 MG 
Human glioblastoma cell line, classified as 
grade IV 
ATCC (HTB-14TM) 
 
2.1.6 Buffers and solutions  
Table 10: Media for bacteria 
 Medium  Components for 1L Preparation 
LB-medium  5 g yeast extract 
10 g peptone 
10 g NaCl 
MQ-water (ddH2O) ad 1L, adjust to pH 7.2, 
autoclave for 30 minutes 
LB-
Ampmedium  
5 g yeast extract 
10 g peptone 
10 g NaCl 
15 g agar-agar 
MQ-water (ddH2O) ad 1L, adjust to pH 7.2, for 
selective LB-agar plates allow media to cool 
down to 50°C before adding selective 
antibiotic(s) 
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Table 11: Supplements 
Media Ingredients for 1 L / 
Concentration 
Preparation 
Kanamycin 25 mg/ml-1 Dissolve in ddH2O, filter sterilize (0.2 µm), store 
at -20°C (1 ml Aliquots) 
Ampicillin 100 mg/ml-1 Dissolve in ddH2O, filter sterilize (0.2 µm), store 
at -20°C (1 ml Aliquots) 
 
Table 12: Buffer for plasmid DNA preparations 
Buffer Ingredients / Concentration 
GTE buffer 
  
  
  
50 mM Glucose 
25 ml Tris-HCl pH 8.0 
10 mM EDTA 
  
Lysis buffer 
  
200 mM NaOH 
1% SDS 
Neutralization buffer 3 M KoAc, pH 5,2 
 
Table 13: Buffer for Annexin-V staining 
Name   Description  
1x binding buffer  10 mM HEPES/NaOH pH 7.4, 140 mM NaCl,  
2.5 mM CaCl2  
 
Table 14: Buffer for agarose gel electrophoresis 
Buffer Ingredients / Concentration 
Running buffer (0.5x TBE) 
  
  
44.5 mM Tris 
44.5 mM boric acid 
1 mM EDTA, pH 8.0 
DNA loading buffer 
  
  
  
  
100 mM EDTA 
1% SDS 
0.25% (w/v) bromphenol blue 
0.25% (w/v) xylenecylanol 
20% (w/v) glycerol 
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Table 15: Buffers for SDS-PAGE gel electrophoresis 
Buffer Ingredients / Concentration 
SDS sample buffer 
  
  
  
  
62.5 mM Tris-HCl, pH 6.8 
2% (w/v) SDS 
20% (w/v) glycerol 
0.1% (w/v) bromphenol blue 
50 mM DTT 
SDS-PAGE running buffer 
  
  
50 mM Tris 
200 mM glycine 
0.15% (w/v) SDS 
 
Table 16: Comassie staining buffer 
Buffer Ingredients / Concentration 
Quick Coomassie staining solution 
  
  
MQ-water (ddH2O) ad 1L 
0.3% HCl conc. 
Coomassie blue R-250, 80 mg / 1L solution 
Coomassie gel stain 
  
  
  
MQ-water (ddH2O) ad 1L 
45% (v/v) methanol 
1% glacial acetic acid 
Coomassie blue R-250, 1 g / 1L solution 
Coomassie gel destain 
  
  
MQ-water (ddH2O) ad 1L 
10% methanol 
10% glacial acetic acid 
 
Table 17: Lysis buffer 
Buffer Ingredients / Concentration 
Bacterial lysis buffer 
  
  
50 mM MES, pH 6.5 
50 mM NaCl 
1 tablet Complete EDTA-free Protease Inhibitor Cocktail ad 
50 ml solution 
RIPA buffer 
  
  
  
  
  
10 mM Tris-HCl, pH 7.4 
20 mM KCl 
1.5 mM MgCl2 
0.5% SDS 
1.3 mM PMSF 
1 tablet Complete EDTA free Protease Inhibitor Cocktail ad 
50 ml solution 
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Table 18: Western blot analysis buffer 
Buffer Ingredients / Concentration 
Blotting buffer 
  
  
48 mM Tris, pH 7.5 
39 mM glycine 
20% (v/v) methanol 
TBS-T 
  
  
25 mM Tris, pH 8.1 
150 mM NaCl 
0.1% Tween20 
Blocking buffer 3% non-fat milk powder in TBS-T 
 
Table 19: Solutions for DH5α cells preparation   
Medium  Components  
Solution A  100mM RbCl2; 50mM MnCl2; 30mM KAc; 10mM CaCl2; 13% glycerin; 
pH 5.8, sterile filtered. 
Solution B  10mM MOPS, 10mM RbCl2; 75mM CaCl2; 13% glycerin; pH 7,0, 
sterile filtered. 
 
Table 20: Media and solutions for cell culture   
Name  Description  Manufacturer  
DMEM  Dulbecc’s modified eagle medium  Gibco BRL, Eggenstein  
AdvancedMEM  modified eagle medium  Gibco BRL, Eggenstein  
FBS  Fetal bovine serum  PAA Laboratories, Pasching  
L-Glutamine  200 mM solution  PAA Laboratories, Pasching  
Penicillin  10,000 U/ml   PAA Laboratories, Pasching  
Streptomycin  10,000 μg /ml  PAA Laboratories, Pasching  
Trypsin-EDTA  0,02% Trypsin; 0.05% EDTA  Gibco, Eggenstein  
DMSO  Dimethylsulfoxide, highly purified  Merck, Darmstadt  
DPBS  Phosphate buffered Saline  PAA Laboratories, Pasching  
 
2.1.7 Kits   
Table 21: Kits used for molecular techniques 
Name Manufacturer 
Plasmid Maxi Kit Qiagen GmbH, Hilden 
Qiaquick® Gel Extraktion Kit Qiagen GmbH,  Hilden 
Omniscript® Reverse Transcription Qiagen GmbH, Hilden 
Amersham ECL Western Blotting Detection GE Healthcare, Munich 
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2.1.8 Antibodies  
Table 22: Primary antibodies for Western blotting 
 Name  Isolated from  Dilution factor  Lot 
number  
Manufacturer  
Anti-human β-Actin Goat 1:2000 E1013 Santa Cruz 
Biotechnology, 
Inc, Europe. 
Anti-human FUBP1 Goat  1:1000 K0905 Santa Cruz 
Biotechnology, 
Inc, Europe. 
Anti-human MMP2  Rabbit 1:1000 Sc-10736 Santa Cruz 
Biotechnology, 
Inc, Europe. 
Anti-human APAF1 Mouse 1:1000 611365 BD Biosciences, 
Europe. 
  
 
Table 23: Secondary antibodies for western blotting  
Name  Isolated from  Dilution factor  Manufacturer  
Anti-goat HRP  Rabbit  1:5000  Invitrogen, Karlsruhe,  
Germany  
Anti-mouse HRP  Sheep  1:2000  GE Healthcare,  
Munich, Germany  
Anti-rabbit HRP  Donkey  1:2000  GE Healthcare,  
Munich, Germany  
 
Table 24: BenchmarkTM Prestainend Protein ladder 
 
 
 
Band 
No. 
Apparent 
molecular 
weight [kDa] 
1 181.8 
2 115.5 
3 82.2 
4 64.2 
5 48.8 
6 37.1 
7 25.9 
8 19.4 
9 14.8 
10 6.0 
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2.1.9 Chemotherapeutics and Small Molecule Compounds 
Table 25: Chemotherapeutics and small molecules 
Name Concentration Preparation Manufacturer 
mitomycin C  0.4 mg/ml Dissolved in ddH2O steril / 
methanol (4:1) 
Roche, Mannheim 
 
2.1.10 Laboratory Equipment 
Table 26: Centrifuges 
Name Manufacturer 
Beckman J2-HS Beckman, Munich 
Biocentrifuge, J2-21M/E with JA-10 and JA-20 rotors Beckman, Munich 
Cold-Centrifuge Megafuge 1.0R Heraeus, Hanau 
Cold-Centrifuge Minifuge GL Heraeus, Hanau 
Desk-Centrifuge Biofuge pico Heraeus, Hanau 
 
Table 27: Incubators 
Name Manufacturer 
Bacterial Incubator Function Line  Heraus, Hanau 
Bacterial-Shaker-Incubator Multitron model  Infors AG, Bottmingen (Switzerland) 
Cell Culture Incubator MCO 17 AI Sanyo Component Europe GmbH, Ingolstadt 
 
Table 28: Heat Blocks and Water bath 
Name Manufacturer 
Cooling-Thermomixer MKR 13 HLC Biotech, Bovenden 
Dri.Block DB-2D Techne Dexford, Cambridge (England) 
Thermomixer Compact for 1.5ml Tubes Eppendorf AG, Hamburg 
Water-Bath  GFL, Burgwedel  
 
Table 29: Electrophoresis 
Name Manufacturer 
BioRad Power Pac 300 BioRad Laboratories, Munich 
DNA Mini-Subcell for Agarose Gels BioRad Laboratories, Munich 
Electrophoresis Power Supply EPS 301 Amersham Pharmacia Biotech 
Gel-Chamber Model Hoefer HE 33 for Mini Gels Amersham Pharmacia Biotech 
Mini-Protean® 3 Cell Gel Chamber BioRad Laboratories, Munich 
Semidry Blotting Unit Semiphor Transphor Unit Hoefer Pharmacia Biotech 
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Table 30: Others 
Name Manufacturer 
Autoclave Tuttnauer Systec 2540 EL Systec, Wettenberg 
Bunsen Burner Model 1230/1 Carl Friedrich Usbeck KG, Radevormwald  
CryoPure tubes 1.8 ml Sarstedt, Nümbrecht 
Fluorescence Microscope Nikon Eclipse Te300  Nikon, Düsseldorf 
Freezer (-20°C) Liebherr, Ochsenhausen  
Freezer CFC Free (-80°C) Sanyo, Wiesbaden  
Freezing container Qualilab, France 
Gene Amp® PCR System 9700 PE Applied Biosystems  
Hypercassette Amersham, Buckinghamshire (England) 
Integra Pipetboy Integra Biosciences, Fernwald  
Laminar Air Flow (NSF 49 BS 5726 DIN (1-4))  Clean Air, Woerden (Netherlands)  
Magnetic-Stirrer Model IKA-Combimag RCH IKA Labortechnik, Staufen  
Microscope for Cell Culture Helmut Hund GmbH, Wetzlar  
Mircowave Sharp R-3V10 Sharp Corp.  
NanoDropTM 1000 Spectrophotometer  Thermo Fischer Scientific, Bonn  
Neubauer Improved Hemocytometer Marienfeld Superior, Darmstadt  
pH-Meter Model PHM 83 autocal  Radiometer, Copenhagen (Denmark) 
Refrigerator (4°C)  Bosch 
Roller RM5 Assistant 348 Karl Hechst GmbH&Co.KG, Sondheim  
Rotate roller Gerlinde Kister, Mühlhausen 
UV-Transluminator with video camera and -
printer  
UVP Inc., San Gabriel (USA) 
vacuum pump KNF Neuberger LABOPORT, Freiburg  
Vortex Genie 2 Scientific Industries, New York (USA) 
 
2.1.11 Chemicals and Reagents 
Table 31: Reagents 
Name Manufacturer 
Acrylamide Solution (Rotiphorese Gel 30) Carl Roth GmbH&Co.KG, Karlsruhe 
Agarose UltraPure (TM) Agarose Invitrogen GmbH, Darmstadt 
Ampicillin AppliChem GmbH, Darmstadt 
APS (10% in H2O) Sigma-Aldrich Chemie GmbH, Steinheim 
Boric Acid Carl Roth GmbH&Co.KG, Karlsruhe 
Bradford Reagent (Roti®-Quant) Carl Roth GmbH&Co.KG, Karlsruhe 
Bromphenol Blue Carl Roth GmbH&Co.KG, Karlsruhe 
Complete Mini Protease Inihibitor 
Cocktail 
Roche, Mannheim 
DTT Sigma-Aldrich Chemie GmbH, Steinheim 
EDTA Sigma-Aldrich Chemie GmbH, Steinheim 
EGTA Sigma-Aldrich Chemie GmbH, Steinheim 
EtBr Carl Roth GmbH&Co.KG, Karlsruhe 
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EtOH Carl Roth GmbH&Co.KG, Karlsruhe 
Glucose Carl Roth GmbH&Co.KG, Karlsruhe 
Glycerol Carl Roth GmbH&Co.KG, Karlsruhe 
Glycine Carl Roth GmbH&Co.KG, Karlsruhe 
HEPES Carl Roth GmbH&Co.KG, Karlsruhe 
Illustra™ dNTP Set GE Healthcare Europe GmbH, Munich 
Isopropanol (2-Propanol) Carl Roth GmbH&Co.KG, Karlsruhe 
KCl  Carl Roth GmbH&Co.KG, Karlsruhe 
MgCl2 Sigma-Aldrich Chemie GmbH, Steinheim 
Na-β-glycerophosphate Sigma-Aldrich Chemie GmbH, Steinheim 
Na-pyrophosphate Sigma-Aldrich Chemie GmbH, Steinheim 
Na2HPO4 Carl Roth GmbH&Co.KG, Karlsruhe 
NaAc Carl Roth GmbH&Co.KG, Karlsruhe 
NaCl Carl Roth GmbH&Co.KG, Karlsruhe 
NaF (Natriumfluorid) Sigma-Aldrich Chemie GmbH, Steinheim 
NaOH AppliChem GmbH, Darmstadt 
Nonfat dried milk powder AppliChem GmbH, Darmstadt 
PMSF Carl Roth GmbH&Co.KG, Karlsruhe 
Ponceau S Solution Sigma-Aldrich Chemie GmbH, Steinheim 
Roti®-Quant Carl Roth GmbH&Co.KG, Karlsruhe 
SDS Carl Roth GmbH&Co.KG, Karlsruhe 
Sodium Chlorid Roth, Karlsruhe 
Sucrose Carl Roth GmbH&Co.KG, Karlsruhe 
TEMED Carl Roth GmbH&Co.KG, Karlsruhe 
Tris Carl Roth GmbH&Co.KG, Karlsruhe 
TrisBase Roth, Karlsruhe 
Triton-X-100 Fluka, Buchs (Switzerland) 
Tween-20 Carl Roth GmbH&Co.KG, Karlsruhe 
 
2.2 Methods 
2.2.1 Bacteria culture 
2.2.1.1 Generation of chemo-competent Escherichia coli (DH5α) cells 
Competence is the ability of bacterial cells to take up DNA from the environment 
which can be artificially achieved by exposure to high concentrations of calcium 
ions, causing permeabilization of the bacterial cell membrane. 5 ml LB medium 
was inoculated with a single colony of E.coli. The bacteria were grown overnight 
at 37°C with shaking at 250 rpm. The following day, the culture was further 
expanded in 300 ml LB medium untill OD of 0.5 was reached. The LB medium was 
collected, incubated on ice for 20 min and was centrifuged at 4°C at a speed of 
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4,000 x g for 10 min. The supernatant was discarded, and the bacterial pellet was 
resuspended in 200 ml ice-cold solution A (Table 19). After incubation on ice for 1-
2 hours, bacteria were centrifuged for 10 min, and the bacterial pellet was 
resuspended in 15 ml ice-cold solution B (Table 19). The resulting competent 
bacterial cells were divided in 200 µl aliquots, frozen in liquid nitrogen and stored 
at -80°C. 
 
2.2.1.2 Transformation of E.coli (DH5α) by heat shock 
The introduction of foreign DNA into competent bacteria is called “transformation”. 
Chemo-competent E.coli bacteria (DH5α) were thawed on ice, and 50 µl of cells 
were mixed with 10-100 ng of plasmid DNA. After incubation on ice for 20 min, 
cells and DNA were subjected to a heat shock at 42°C for 90 sec, after which they 
were incubated on ice for 2 min. 500 µl of LB medium without antibiotics was 
added, and the bacterial culture was incubated at 37°C for 40 min at 250 rpm. 
Bacteria were then centrifuged at 4,000 x g for 1 min. The supernatant was 
discarded, and the pellet was resuspended in 100 µl LB medium. The resulting 
transformed bacteria were streaked on LB-ampicillin agar plates and incubated 
overnight at 37°C.  
 
2.2.1.3 Storage of transformed bacteria 
For long-term storage, 0.5 ml overnight culture-containing transformed bacteria 
were mixed with 0.5 ml sterile 100% glycerol and immediately frozen at -80°C. 
 
2.2.2 DNA isolation and analysis 
2.2.2.1 Plasmid DNA isolation (Mini-prep) 
For small scale isolation of plasmid DNA from bacterial cells, alkaline lysis of 
bacteria in NaOH-SDS buffer was performed. NaOH causes denaturation of 
chromosomal and plasmid DNA, while SDS denatures proteins. Neutralization with 
potassium acetate leads to precipitation of SDS and formation of large complexes 
containing denatured proteins, chromosomal DNA and cellular debris. After 
removal of these complexes by centrifugation, plasmid DNA in the supernatant 
was concentrated by ethanol precipitation, and RNA was degraded by RNAse-A 
treatment. 3 ml LB medium (containing 100 µg/ml ampicillin) was inoculated with 
one single colony of transformed E.coli bacteria (DH5α) and incubated overnight 
at 37°C while shaking at 250 rpm. 1.5 ml of this culture was centrifuged at 12,000 
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x g for 2 min, the supernatant was discarded and the bacterial pellet was 
resuspended in 100 µl GTE solution by vortexing. After addition of 200 µl NaOH-
SDS, the solution was mixed by inverting the tubes (5 times) and incubated at room 
temperature for 5 min. For precipitation of proteins and genomic DNA, 150 µl 5M 
KOAc was added and mixed carefully by inversion, followed by incubation on ice 
for 5 min. The samples were centrifuged at 12,000 x g for 5 min, the supernatant 
was transferred to a new Eppendorf tube, and the DNA was precipitated with 1 ml 
100% ethanol (centrifugation at 12,000 x g, 10 min). The pellet was washed with 
70% ethanol, and after centrifugation, the DNA was air-dried and resuspended in 
30 µl sterile deionized H2O containing 0.2 mg/ml RNAse A (Roche, Mannheim). 
The isolated plasmid DNA was stored at –20°C. 
 
2.2.2.2 Isolation of plasmid DNA for large-scale preparations (Maxi-prep) 
For the amplification of large amount of plasmid DNA, the plasmid of interest was 
transformed into competent E.coli bacteria (DH5α) and the resulting ampicillin-
resistant bacteria were grown overnight at 37°C with shaking at 170 rpm in 250 ml 
LB medium containing 100 μg/ml ampicillin. Bacterial cells were harvested by 
centrifugation at 6,000 x g for 15 min at 4°C, and plasmid DNA was isolated using 
a commercially available kit (Qiagen and Macherey-Nagel). 
Purification of plasmid DNA was performed according to the manufacturer´s 
instructions. In brief, bacterial cells were lysed, and plasmid DNA was immobilized 
on an anion-exchange column, washed and eluted using a buffer with high salt 
concentrations. After precipitating with isopropanol and washing with 70% ethanol, 
the DNA was air dried and dissolved in sterile deionized water. 
 
2.2.2.3 DNA concentration measurement 
The DNA concentration was determined using a “Nanodrop” device. 2µL of purified 
plasmid preparation was spotted on the lower pedestal, and the absorption at a 
wavelength of 260 nm (caused by de-localized π-electrons of purin or pyrimidine 
bases) was measured. To determine the purity of the DNA sample, the absorption 
at a wavelength of 280 nm (absorption by aromatic amino acid side chains) was 
measured.  
A sufficient purity should be indicated with an absorption ratio of A260 / A280: 1.7 
- 2 
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2.2.2.4 Agarose gel electrophoresis 
Agarose gel electrophoresis is a method for the detection of DNA fragments and 
can be used to determine the size and the concentration of DNA molecules. 
Agarose forms a meshwork in which DNA can migrate, and application of an 
electric field causes movement of the negatively charged DNA towards the anode. 
During this process, DNA molecules are separated based on their size. Due to the 
addition of the intercalating dye ethidium bromide, DNA becomes visible upon UV 
light illumination. Plasmid DNA or PCR products were separated in 1-2% agarose 
1 x TBE or TAE gels with 0.5 µg/ml ethidium bromide. Electrophoresis was 
performed in 0.5 x TBE or 1 x TAE buffer. DNA samples were mixed with 6 x DNA 
loading buffer, loaded onto agarose gels and separated at 10 V/cm gel length. A 1 
kb DNA ladder or the 100 bp DNA ladder (Fermentas) was used as a marker.  
 
2.2.3 Polymerase chain reaction (PCR) 
The Polymerase chain reaction (PCR) is a method for the amplification of specific 
DNA sequences. Template DNA is incubated with the enzyme DNA polymerase in 
the presence of oligonucleotide primers, which possess a complementary 
sequence to the target DNA, and deoxyribonucleotide triphosphates (dATP, dCTP, 
dGTP, dTTP). The reaction is conducted in repeated thermal cycles that consist of 
three main steps: melting of template DNA (95°C), annealing of primers and 
template (52-60°C, depending on primer annealing temperatures), and DNA 
elongation (68-72°C, depending on the enzyme used). Heating to 95°C inactivates 
most DNA Polymerases and therefore, heat-stable enzymes like the Thermus 
aquaticus (Taq) Polymerase are commonly used. The annealing temperature of 
primers is calculated using the following equation (Rychlik et al., 1990): 
 
Annealing temperature = (number of G and C) x 4°C + (number of A and T) x 2°C 
 
The time of elongation depended on the length of the sequence to be amplified, in 
general 1 min for 1 kb was used. PCR reactions for cloning of the amplified 
sequence were performed with Pfx polymerase (5 u/µl, Roche, Mannheim). The 
reaction mixtures were prepared and kept on ice until the thermocycler 
temperature reached 94°C (simplified hot start). 
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Template DNA  10 ng - 100 ng 
dNTP-mix (2.5mM each)  6 µl 
Primer 1 and 2 (10µM)  1.5 µl each 
MgSO4 (25mM)  2 µl 
10 x Pfx amplification buffer  5 µl 
Pfx polymerase  0.8 µl 
H2O  ad 50 µl 
 
For cloning PCR reactions, the following PCR protocol was used (annealing 
temperatures and elongation times were adapted for each specific reaction): 
 
 
 
 
 
 
 
The amplification of DNA fragments was performed in a GeneAmp® 9700 
thermocycler (Perkin Elmer, Weiterstadt). PCR products were separated by 
agarose gel electrophoresis, isolated with the QIAquick gel extraction kit (Qiagen, 
Hilden) and either used directly for further cloning or stored at –20°C. 
 
2.2.4 RNA isolation and analysis 
2.2.4.1 RNA isolation 
For RNA isolation, cells were washed with PBS, trypsinyzed and collected with 
DMEM in a Falcon tube. After centrifugation (5 min, 400 x g, 4°C), cells were used 
immediately for RNA isolation. Purification of total RNA was performed using the 
RNeasy Mini Kit (Qiagen, Hilden) according to the manufacturer´s instructions. 
In brief, cells were lysed using QIA shredder columns (Qiagen, Hilden), and RNA 
was immobilized on silica-membrane columns. On-column DNAse I digestion was 
performed to remove contaminating DNA, and after washing, RNA was eluted 
using RNAse-free water. 
 
 
Denaturation  94°C 3 min 
Amplification (35 cycles)  94°C 1 min 
58°C  1 min 
68°C  3 min 
Final Elongation  68°C  10 min 
Cooling  4°C  ∞ 
Materials and Methods 
 
37 
 
 
2.2.4.2 Quantification of RNA concentration 
RNA concentration was determined using a NanoDrop 1000 Spectrophotometer 
(Thermo Scientific) by measurement of the absorption at a wavelength of 260 nm. 
260/280 and 260/230 absorption ratios were determined to assess RNA purity. The 
260/280 ratio should be in the range of 1.8- 2.0, and the 260/230 ratio should be 
between 2.0 and 2.2 for clean RNA preparations (280 nm: absorption by 
contaminating proteins, 230 nm: absorption by different contaminating organic 
compounds). 
 
2.2.4.3 Reverse transcription 
RNA was converted into cDNA using Omniscript RT kit (Qiagen) according to the 
manufacturer´s instructions. In brief, 1 µg of RNA was added to a 20 µl reaction 
mix containing RT reaction buffer, oligo (dT), random hexamer primer, dNTPs, 
RNAse inhibitor (RiboLock, Fermentas) and Reverse Transcriptase (RT). Control 
reactions were performed without Reverse Transcriptase (RT control). 
 
2.2.4.4 Quantitative real time PCR (qPCR) 
The copy number of RNA or DNA molecules in cells (e.g. cultivated cells or tissue 
samples) can be determined by quantitative real time PCR, whereas isolated DNA 
can directly be used as a template for qPCR analysis. A reverse transcription 
reaction has to be performed for the analysis of RNA, and the obtained cDNA is 
further used in qPCR analysis. 
In principle, qPCR is a method based on a conventional PCR reaction. It is 
performed in the presence of a fluorescent agent whose amount bound to amplified 
DNA is determined during the course of the reaction as an indicator of the amount 
of amplified target sequence. Quantification of the fluorescent signal allows to 
monitor target amplification not only at the end of the reaction as in a conventional 
PCR but throughout all PCR cycles. Two different kinds of fluorescent dyes are 
commonly used for qPCR: non-specific dyes that intercalate into DNA double-
strands (eg. SYBR Green) and/or specific DNA probes (oligonucleotides labeled 
with a fluorescent reporter) that bind to the amplified target sequence. Specificity 
of qPCR assays based on dyes like SYBR Green can be ensured by the 
combination of melting curve and agarose gel analysis together with sequencing 
of the reaction product. For quantification of the target sequence, the acquired 
fluorescence is plotted against the number of PCR cycles. A fluorescence 
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background threshold is defined, and the cycle at which the measured signal 
crosses this threshold (the cycle threshold or Ct value) is determined for each 
sample.  
 
2.2.4.5 qPCR analysis using SYBR Green-based assays 
The expression levels of mRNAs in murine cells were analyzed by SYBR Green-
based qPCR assays. For this purpose, RNA was isolated, and a reverse 
transcription was performed as described in sections 2.1.5.1 and 2.1.5.3. For each 
sample, qPCR reactions were performed in triplicates in a reaction volume of 24 
µl. The reaction mix contained 1 x ABsoluteTM QPCR SYBR Green mix (Thermo 
Scientific), gene-specific primers (500nM each) and 30 ng cDNA per reaction. To 
ensure the absence of DNA contamination, reactions with water or cDNA samples 
without RT were performed. Assays were carried out on a LightCycler®480 
(Roche) with white LightCycler®480 Multiwell plates 96, and the following PCR-
protocol was applied: 
 
Denaturation 95°C 15 min 
Amplification (40 cycles)  95°C 20 sec 
58°C 30 sec 
72°C 30 sec 
Melting Curve  50°C 10 sec 
+2.2°C  10 sec 
... 95°C target temperature 
 
2.2.5 Protein biochemistry 
2.2.5.1 Immunoblotting of proteins („Western blot analysis“) 
2.2.5.1.1 Protein extraction from mammalian cells 
For extraction of proteins, cultured mammalian cells were washed with PBS and 
either scraped from the culture plates with a rubber-policeman or trypsinized and 
collected with DMEM in a Falcon tube. After harvesting by centrifugation (5 min; 
1,500 rpm; 4°C), cell pellets were resuspended in 1 ml PBS and transferred into a 
1.5 ml Eppendorf tube. Cells were again pelleted by centrifugation (5 min; 1,500 
rpm) and resuspended in 150-500 µl freshly prepared lysis buffer (depending on 
cell numbers e.g. 150 µl for 1x106 cells). Lysis of cells was performed by incubation 
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on ice for 20 min followed by sonification (Sonifier 250, Branson; Duty Cycle 30%, 
Output 3, 20 pulses). 
 
 
2.2.5.1.2 Measurement of protein concentration according to the Bradford 
protocol 
The protein concentration of cell lysates was determined by the Bradford assay. 
The basic principle of this assay uses the absorbance maximum shift of acidic 
Coomassie Brilliant Blue G-250 solution from 465 nm to 595 nm that occurs after 
binding of the dye to proteins. This change in colour is caused by the stabilization 
of the anionic form of the dye by hydrophobic and ionic interactions between dye 
and protein. Protein concentrations were determined according to the 
manufacturer´s instructions (Roti®-Quant, Carl Roth, Karlsruhe). In brief, 2 μl of 
cell lysate were diluted in 800 μl water and 200 μl Bradford solution and incubated 
for 5 min at room temperature. The protein concentration was measured at 595 nm 
with a spectrophotometer and calculated using a BSA standard curve. 
 
2.2.5.1.3 SDS- polyacrylamide-gel electrophoresis (PAGE) 
SDS-PAGE is a method by which proteins can be separated depending on their 
molecular weight. Gels are formed by polymerization of acrylamide solution which 
results in the formation of a meshwork of polyacrylamide. The size of the pores in 
the gel depends on the percentage of acrylamide used. Higher concentrations of 
acrylamide are used for the separation of smaller proteins. Proteins migrate in the 
gel after application of an electric field. As the proteins are denatured by the 
negatively charged detergent sodium dodecyl sulfate (SDS) and reduced by ß-
mercaptoethanol, which breaks S-S linkages, they migrate towards the anode, and 
the velocity of their migration is determined by the molecular weight of the protein. 
Protein samples are applied onto the stacking gel which has a low percentage of 
SDS and polyacrylamide, and the proteins migrate into the gel due to the electric 
field. At the boundary between stacking and separating gel, movement of the 
proteins is decelerated and a sharp frontline of the migrating samples is formed. In 
the separating gel, proteins with lower molecular weight move faster than proteins 
with high a molecular weight. SDS-gels were produced with the following 
compositions: 
Protein samples were denatured for 5 min at 95°C in 5 x sample buffer, and 
separation by SDS PAGE was performed in 1 x SDS-PAGE buffer using the Mini- 
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Protean II system (BioRad, Munich). Electrophoresis was performed at 80 V for 
the stacking gel and 120 V for the running gel. The protein marker BenchMarkTM 
Prestained Protein Ladder (Invitrogen, Karlsruhe) was used to determine the size 
of the protein run. Subsequently, proteins were detected by immunoblotting 
(Western blot analysis). 
 
 
2.2.5.1.4 Protein transfer onto nitrocellulose membranes 
For the detection of proteins by specific antibodies, protein transfer onto 
nitrocellulose membranes was performed after SDS-PAGE. Nitrocellulose transfer 
membranes (Schleicher & Schuell BioScience, Dassel) and Whatman papers were 
soaked in 1 x blotting buffer. The SDS gel was placed on the nitrocellulose 
membrane and was sandwiched between 3 layers of Whatman papers on top of 
the anode of a semi-dry blotting chamber (Keutz, Reiskirchen) and again 3 
Whatman papers on the cathode of the blotting chamber. Protein transfer was 
performed at 50 V and 55 mA for 2 h. After blotting, membranes were stained with 
Ponceau S solution to confirm equal transfer of proteins from the gel. 
 
 
2.2.5.1.5 Immunodetection of blotted proteins 
Following protein transfer, unspecific protein binding sites of the nitrocellulose 
membranes were blocked by incubation in blocking buffer (5% non-fat milk and 
0.1% Tween in 1 x PBS for ECL detection or Odyssey Blocking Buffer for detection 
using the Odyssey system) for at least 2 hours at room temperature or at 4°C 
overnight. For specific protein detection, the respective antibodies were diluted in 
blocking buffer, and membranes were incubated for 1 hour at room temperature or 
at 4°C overnight. Membranes were then washed 3 x 10 min with PBS-T (1 x PBS 
+ 0.1% Tween) to remove unbound antibody. Membranes were then incubated 
with the corresponding secondary antibody diluted in blocking buffer. The 
secondary antibody was either coupled to Horseradish Peroxidase (HRP) for ECL 
detection or to IR (Infrared) dyes for detection with the Odyssey system. After 
incubation for 1 hour at room temperature, membranes were washed for 3 x 10 
min with PBS-T. Secondary antibody signals were then measured by ECL chemo-
luminescence or with the Odyssey system. 
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Detection of proteins by ECL (Luminiscence assay) 
 
Secondary antibodies coupled to the enzyme Horseradish Peroxidase (HRP) are 
commonly used for specific detection of proteins. This enzyme converts the 
substrate luminol into 3-aminophthalate which then emits light with a wavelength 
of around 428 nm. Addition of chemicals like modified phenols to the solution leads 
to enhanced chemiluminiscence (ECL). 
In this work, the ECLTM Western blot reagents (GE Healthcare, Munich) were used 
for detection of proteins by Western blot Analysis. After incubation of nitrocellulose 
membranes with ECL, a sensitive film (SuperRX, Fujifilm) was exposed onto the 
membrane and developed using an Optimax X-Ray Film Processor (Protec- 
Medizintechnik, Oberstenfeld). 
 
Detection of proteins using the Odyssey system 
 
An alternative method to the use of HRP-coupled secondary antibodies is the use 
of antibodies coupled to fluorescent dyes that can be detected by corresponding 
scanners. In this work, the Odyssey infrared imaging system (Li-Cor, Bad 
Homburg) was used. Secondary antibodies for this system were coupled to 
infrared dyes that emit light at a wavelength of either 800 or 680 nm. 
 
2.2.6 Luciferase reporter assay 
The ability of miRNA’s to influence the activity of the FUBP1 3’UTR was tested in 
Luciferase reporter assays. For this purpose, the 3’UTR of the Luciferase-
containing pISO reporter construct (Addgene, Cambridge, USA) was cloned with 
3’UTR of human FUBP1. The predicted miRNA binding sites were mutated by base 
pair changes using DpnI mediated site-directed mutagenesis. Hep3B cells were 
co-transfected with wild type or mutated FUBP1 3’UTR plasmid, Renilla 
normalization plasmid (pGL 4.74) and pcDNA vector to level out DNA amounts 
using the transfection reagent Attractene (QIAGEN, Hilden, Germany). 
Transfected cells were harvested after 48 hours and lysed in 1 x Passive Lysis 
Buffer (Promega, Mannheim). Lysates were analyzed using the Dual-Luciferase™ 
Reporter Assay System (Promega, Mannheim) according to the manufacturer´s 
instructions. Luciferase activity was quantified using a LUMI Star Galaxy 
Luminometer (BMG Labtech, Offenburg). 
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2.2.7 Mammalian cell culture 
2.2.7.1 Culture of mammalian cells 
Cells were cultured in a BBD-6220 incubator at 37°C with 5% CO2 in a humidified 
atmosphere. Cells were grown in DMEM medium (Dulbecco´s modified Eagles 
medium) containing 10% v/v fetal bovine serum (FBS), 1% v/v L-Glutamin 
(100mM) and 1% v/v Penicillin/Streptomycin (10 µg/ml). For inactivation of the 
complement system, FBS was incubated at 56°C for 30 min before use. 
Cells were usually passaged twice a week to prevent them from becoming 
confluent. After the removal of the medium by aspiration, cells were carefully 
washed with DPBS and treated with Trypsin for 5 - 10 minutes to detach cells from 
the culture dish. Afterwards, cells were resuspended in appropriate cell culture 
medium and 1/3 to 1/14 of the cells were transferred to a new culture plate with 
fresh medium. 
 
2.2.7.2 Freezing and thawing of cells 
For long-term storage, cells were frozen in FBS containing 10% dimethyl sulfoxide 
(DMSO). This organic solvent reduces the formation of ice crystals that can 
damage the cell membrane during the freezing process. Cells were washed and 
trypsinized as for passaging, resuspended in fresh medium and transferred to a 
Falcon tube (Becton Dickinson Biosciences, Heidelberg). The cells were harvested 
by centrifugation (5 min, 400 x g, 4°C), resuspended in FBS plus 10% DMSO and 
transferred into a cryo tube (Nunc, Wiesbaden). These tubes were stored in a 
freezing container (Cryo1°C, Nalgene, Roskilde, Denmark) in the -80°C 
refrigerator overnight and then moved to the liquid nitrogen storage tank. 
 
For thawing, cells were kept under the sterile hood at room temperature until they 
defrosted and were then resuspended in cell culture medium and harvested by 
centrifugation (5 min, 400 x g, 4°C). The medium was aspirated to remove residual 
DMSO, cells were resuspended in fresh medium and transferred into cell culture 
dishes. 
 
2.2.7.3 Determination of cell numbers using a hemacytometer 
For quantification of cell numbers, 10 µl of a cell solution was transferred into a 
Neubauer hematocytometer (Baxter Scientific), and cells in 16 squares were 
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counted under the microscope in a 100x magnification. The cell number was 
calculated using the following equation: 
Counted cell number x 104 = cell number/ml 
 
2.2.7.4 Transfection of mammalian cells 
Foreign DNA can be introduced into mammalian cells by transfection. DNA can be 
integrated in larger complexes that are taken up by cells by endocytosis or 
phagocytosis. Also, pores in the cell membrane can be generated by 
electroporation which leads to uptake of DNA from the cell culture medium. 
Depending on the cell type, different methods show different efficiencies. 
Therefore, transfection protocols have to be adapted for each individual cell line. 
 
2.2.7.5 Polyethyleneimine (PEI)-mediated transfection 
For transfection, a 10mM working solution of PEI (Sigma) was used. PEI 
transfection is most efficient when the ratio between postively charged amine 
nitrogens in PEI and negatively charged phosphates of the DNA backbone lies in 
the range of 9-13.5 (Boussif et al., 1995).  
1 µg of DNA and 2.7 µl of 10mM PEI were diluted in 150 µl DPBS in separate 
Eppendorf tubes. Both solutions were then mixed by vortexing and incubated at 
room temperature for 15 min. Cells were washed, and serum-free medium was 
added. After 4 hours, medium was aspirated and replaced by medium containing 
serum, glutamine and penicillin streptomycin. 
 
2.2.7.6 LipofectamineTM 2000-mediated transfection 
LipofecatineTM 2000 was used according to the manufacturer´s instructions. 
Transfection was performed in medium without antibiotics. 2.5 µl Lipofectamine 
were used for the transfection of 1 µg DNA. DNA and Lipofectamine were diluted 
in 50 µl Opti-MEM reduced serum medium in separate tubes. Both solutions were 
mixed by pipetting and incubated at room temperature for 15-20 min before adding 
the mixture to the cells. After 4 hours, medium was aspired and replaced by fresh 
medium. 
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2.2.7.7 Lentiviral transduction of mammalian cells 
2.2.7.7.1 Lentivirus production in HEK-293T cells 
For lentivirus production, HEK-293T cells were transfected with the respective 
lentiviral construct and two packaging plasmids (pCMV-dR8.91 & pMD2.G) 
containing structural virus proteins. 3x106 HEK-293T cells were seeded per 10 cm 
dish and transfected with 10 µg of total DNA (1.75 µg pMD2.G, 3.25 µg p8.91 and 
5 µg expression vector) using PEI. 48 hours after transfection, virus supernatant 
was collected, filtered through a 0.45 µg syringe filter unit, centrifuged (20,000 rpm, 
40C, 2:20 hrs) and aliquoted into PCR tubes (15 µL each) 
 
2.2.7.7.2 Lentiviral transduction 
For transduction, 1x105 cells were seeded in 6 well plates 24 hours before 
transduction. Lentivirus-containing supernatant or concentrated virus aliquots was 
diluted with fresh medium to a total volume of 6 ml/well to achieve a multiplicity of 
infection (MOI) of 10. To achieve higher transduction efficiencies, polybrene was 
added to the medium to a final concentration of 8 µg/ml, and cells were centrifuged 
at 250 x g and 32°C for 50 min (spin infection). 
 
2.2.8 Apoptosis assay 
To test the sensitivity of different cells to apoptotic stimuli, cells were plated at 
3x105 in 6 well plates. For apoptosis induction, cells were treated with TRAIL or 
MG132 (proteosomal inhibitor). Concentrations and incubation times were 
modified according to the particular cell line. After incubation, cell culture 
supernatant was collected (to include apoptotic, detached cells in the analysis), 
and adherent cells were harvested using Trypsin. Cells were washed in PBS and 
fixed for flow cytometric analysis following the Nicoletti protocol.  
 
2.2.8.1 Nicoletti assay 
A typical feature of apoptosis is the fragmentation of genomic DNA which can be 
measured by different techniques to discriminate between living and apoptotic 
cells. Propidium iodide (PI) is a dye which specifically intercalates into nucleic acids 
which can be used to quantify DNA fragmentation by flow cytometry. For this 
purpose, cells were fixed with ethanol and stained with PI in the presence of 
RNAse-A. After RNA digestion, the PI signal intensity was comparatively equal to 
the DNA content of a cell hence, the cell cycle profile for all the cells could be 
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determined. As ethanol fixation permeabilizes the cell membranes, fragmented 
DNA is lost from apoptotic cells and therefore, apoptotic cells display a subG1 
content of DNA (Riccardi and Nicoletti, 2006). 
Cells were harvested and transferred to FACS tubes. After centrifugation (5 min, 
400 x g, 4°C), they were washed with PBS and again pelleted. Cells were fixed by 
adding 1 ml ice-cold 70% ethanol and after thorough mixing, incubated at 4°C for 
at least 12 hours (up to two weeks). Before staining, cells were washed with 38mM 
Na-Citrate (pH 7.4), centrifuged (5 min, 400 x g, 4°C) and 200- 500 µl of staining 
solution were added. Staining was performed for 20 min at room temperature in 
the dark. Acqusition of cell cycle profiles was done on a Becton Dickinson 
Biosciences FACS Calibur. PI fluorescence was measured in the FL2 channel after 
activation of the doublet discrimination module (DDM), and data sets were 
analyzed using Cell Quest-Pro software (Becton Dickinson Biosciences, 
Heidelberg). At least 20,000 events were acquired for each sample. Staining 
solution: 38mM Na-Citrate (pH 7.4), 50 µg/ml propidium iodide, 5 µg/ml RNAse A 
 
2.2.9 Proliferation assay 
2.2.9.1 Click-iT™ EdU assay 
2x105 Hep3B cells were seeded into 6 well plates in DMEM with 10% FBS. The 
next day, cells were incubated with 10µM 5-ethynyl-2’-deoxyuridine (EdU) for 1 
hour. After harvesting of the cells using Trypsin, cells were washed with 1% BSA 
in PBS. Cells were fixed using Click-iT™ fixative solution provided in the kit and 
incubated in dark for 15 minutes. Cell were further washed with 1% BSA in PBS 
and permeabalized using Click-iT™ saponin-based permeabilization reagent for 
15 minutes. Cells were further incubated in dark for 30 minutes with Click-iT™ 
reaction cocktail (PBS, CuSO4, fluorescent dye azide and reaction buffer) and 
washed with Click-iT™ saponin-based permeabilization reagent. Cells were further 
stained with Alexa Fluro® 647 and analysed using flow cytometer. 
 
2.2.10 miRNA quantification using qRT-PCR 
To quantify miRNA levels, cDNA was reverse transcribed from total RNA samples 
using specific miRNA primers from the TaqMan MicroRNA Assays and reagents 
from the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems). The 
resulting cDNA was amplified by PCR using TaqMan MicroRNA Assay primers 
with the TaqMan Universal PCR Master Mix and analyzed with a 7500 ABI PRISM 
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Sequence Detector System according to the manufacturer's instructions (Applied 
Biosystems). The relative levels of miRNA expression were calculated from the 
relevant signals by the ΔΔCt method by normalization to the signal of RNU48. 
 
2.2.11 miRNA target prediction 
In order to identify the miRNAs that regulate FUBP1, the following software 
programme for analysis were used: TargetScan (http://www.targetscan.org/), 
PicTar (http://pictar.mdc-berlin.de/) and miRanda (http://www.microrna.org) were 
used. Only those miRNA target predictions that were found in at least two 
databases were accepted as reliable. 
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3.1 Analysis of FUBP1 expression in glioblastoma cell lines 
 
FUBP1 has been known to activate the proto-oncogene c-myc (Duncan, Bazar et 
al. 1994) and was shown to act as an onco-protien in HCC in Prof. Martin Zörnig’s 
lab (Rabenhorst, Beinoraviciute-Kellner et al. 2009). In general, FUBP1 was found 
to be expressed in a broad range of normal tissues. An increased expression of 
FUBP1 was observed in glioblastoma cells when compared to normal 
oligodendrocytes and astrocytes (Rabenhorst U 2010). However, previous studies 
revealed that inactivating mutations in the genes CIC and FUBP1 contribute to 
human oligiodendrogioma (Bettegowda, Agrawal et al. 2011). Therefore, the role 
of FUBP1 in glioblastoma was investigated in detail. The expression of FUBP1 in 
different glioblastoma cell lines was analysed by western blotting. The analysis 
revealed that FUBP1 is differentially expressed in a variety of glioblastoma cell 
lines. LN-308, SKMG-3 and U-138 MG cells showed higher expression of FUBP1 
compared to LNT-229, LN-428 and U-373 MG (with moderate expression) and U-
87 MG (showing the lowest expression) (Figure 6)   
 
 
Figure 6: FUBP1 expression in different glioblastoma cell lines. 
Seven different glioblastoma cell lines were cultured, and FUBP1 expression was tested by 
immunoblotting with a FUBP1-specific antibody. Immunoblotting analysis revealed differential 
expression of FUBP1 in a variety of cell lines. 80 µg of each cell lysate was loaded for Western blot 
analysis. Ponseau S staining was used as a loading control. 
3. Results  
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3.2 Functional analysis of FUBP1 in glioblastoma cell lines by gene 
silencing 
 
To study whether FUBP1 overexpression plays a crucial role and is of functional 
relevance in glioblastoma, the consequences of FUBP1 knockdown in the 
glioblastoma cell lines LNT-229, SKMG-3, LN-428, U-138 MG, U-87 MG and U-
373 MG were analyzed. For this purpose, FUBP1-specific shRNAs were cloned 
into the lentiviral expression vector pSEW. Lentivirus was produced in HEK-293T 
cells and used for stable transduction of LNT-229, SKMG-3, LN-428, U-138 MG, 
U-87 MG and U-373 MG cells. In addition to vector-containing FUBP1-specific 
shRNA, the scrambled shRNA served as a control. FUBP1-specific shRNA led to 
a significant downregulation of FUBP1 protein levels in all the cell lines (Figure 7).  
 
 
 
  
 
Figure 7: Knockdown of FUBP1 expression in the glioblastoma cell lines LNT-229, SKMG-3, 
LN-428, U-138 MG, U-87 MG and U-373 MG. 
LNT-229, SKMG-3 (A), LN-428, U-138 MG (B), U-87 MG & U-373 MG (C) cells were transduced with 
lentiviral particles containing either empty pSEW vector or pSEW-FUBP1 shRNA. Following two 
passages after transduction, the knockdown efficiency was tested by immunoblotting with a FUBP1-
specific antibody. Transduction of FUBP1shRNA led to a strong downregulation of the FUBP1 
protein. 80 µg of each cell lysate was loaded for Western blot analysis. β-Actin was visualized as a 
loading control. 
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3.3 Consequences of the FUBP1 knockdown on apoptosis rates in the 
glioblastoma cell lines LNT-229, SKMG-3, LN-428, U-138 MG, U-87 MG 
and U-373 MG. 
 
Inhibition of apoptosis is one of the major events contributing to cancer 
progression. The knockdown of FUBP1 has already been shown to enhance 
apoptosis in HCC cells. Glioblastoma cells are resistant to many apoptotic stimuli. 
LNT-229, SKMG-3, LN-428, U-138 MG, U-87 MG and U-373 MG cells stably 
transduced with empty pSEW vector and pSEW-sh2FUBP1 were treated with 250 
ng/mL TRAIL and 2.5 µM MG132 for the induction of apoptosis. After incubation 
for 6-7 hours, cells were harvested and fixed with ethanol. The percentage of 
apoptotic cells was determined by propidium iodide staining followed by flow 
cytometric analysis. LNT-229, SKMG-3, LN-428, U-138 MG FUBP1- deficient cells 
displayed a significantly higher percentage of apoptotic cells compared to control 
cells (Figure 8 (A), (B), (C) & (D)). In contrast, U-87 MG and U-373 MG cells 
bearing the FUBP1 knockdown were much more resistant to apoptotic stimuli 
compared to control cells (Figure 8 (E) & (F)). To some extent, untreated 
knockdown cells died to a greater extent than the untreated LNT-229, SKMG-3 
and U-138 MG & LN-428 control cells (Figure 8 (A-D). This is not the case in U-87 
MG and U-373 MG (Figure 8 (E-F))   
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Figure 8: Influence of a FUBP1 knockdown on apoptosis in LNT-229, SKMG-3, LN-428, U-138 
MG, U-87 MG and U-373 MG 
3x105 LNT-229, SKMG-3, LN-428, U-138 MG, U-87 MG and U-373 MG (pSEW vector or pSEW-
FUBP1 shRNA) cells were seeded into six-well plates. 24 hours later, apoptosis was induced by 
MG132 (2.5 µM) and recombinant TRAIL (250 ng/mL). Cells were harvested after incubation for six 
hours. Apoptotic cells were identified by staining with propidium iodide, and the dead cells were 
measured by FACS. Apoptotic cells display a subG1 DNA content. Mean and standard deviation are 
shown for three independent experiments. 
 **: p<0.01, ***: p<0.001.  
 
3.4 Consequences of a FUBP1 knockdown on cell proliferation in the 
glioblastoma cell lines LNT-229 and U-87 MG 
 
Next, the importance of FUBP1 expression for glioblastoma cell proliferation was 
tested. LNT-229, LN-428, U-138, U-87 MG and U-373 MG cells stably transduced 
with empty pSEW vector or pSEW-shFUBP1 were labelled with 10 µM EdU for 1 
hour and subsequently fixed, washed, and incubated with Click-iT™ reaction 
cocktail 30 minutes. Further cells were stained with Alexa Fluro® 647 and analysed 
using flow cytometer. LNT-229 and LN-428 FUBP1-deficient cells contained 
significantly less EdU positive cells (corresponding to less cells in the S-phase of 
the cell cycle during incubation time with EdU) compared to control cells with 
normal FUBP1 levels. Surprisingly, U-87 MG and U-373 MG cells bearing a FUBP1 
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knockdown comprised more EdU positive cells compared to control cells (Figure 
9). However, there was no change in the proliferation rates within control and 
FUBP1 knockdown U-138 MG cells.  
 
 
 
 
Figure 9: Influence of a FUBP1 knockdown on cell proliferation in LNT-229 and U-87 MG 
3x105 LNT-229, LN-428 and U-138 MG (pSEW vector and pSEW-FUBP1 shRNA transduced (A, B 
and E)) and U-87 MG and U-373 MG (pSEW vector or pSEW-FUBP1 shRNA transduced (C and D)) 
cells were seeded into six well plates. The next day, cells were treated with 10µM EdU for 2 hrs and 
stained with APC-labelled anti-EdU antibody as described by the manufacturer’s protocol. EdU-
positive cells were measured by flow cytometry. Mean and standard deviation are shown for three 
independent experiments. **: p<0.01, ***: p<0.001.  
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3.5 FUBP1-deficient U-87 MG cells displayed a higher vascular tube 
formation capacity compared to LNT-229 FUBP1 knockdown cells 
 
To investigate the capacity of U-87 MG and LNT-229 cells which had shown 
opposite effects in the apoptosis and proliferation assays, to undergo 
vasculogenesis in cell culture, I used a matrigel tube formation assay. U-87 MG 
FUBP1-deficient cells underwent a dramatic re-organization and formed an 
efficient vasculogenic network of tubular structures within two days. U-87 MG 
control cells were clustered in groups, and less vascular tube formation was 
observed as with the cells lacking FUBP1. In contrast, LNT-229 FUBP1 knockdown 
cells formed hardly any structures, and all the cells died. LNT-229 control cells 
showed less events of tubular formation when compared to U-87 MG control cells. 
In addition, FUBP1- deficient U-87 MG cells, when cultured for a longer time 
period, formed a higher number of spheroids compared to U-87 MG control cells 
which might be due to an upregulation of pro-proliferative and/or angiogenic genes 
upon FUBP1 knockdown (Figure 10).   
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Figure 10: Influence of a FUBP1 knockdown on vascular tube formation in LNT-229 and U-87 
MG 
Matrigel was layered on a well of a 24 well plate and incubated until it had become semi-solid. 3x105 
LNT-229 (pSEW vector or pSEW-FUBP1 shRNA transduced (A)) or U-87 MG (pSEW vector and 
pSEW-FUBP1 shRNA transduced (B)) cells were seeded on the matrigel and incubated for 24 hours 
in serum-free medium. Microscopic pictures were taken, and spheroids and vascular tube formation 
were observed.  
 
3.6 FUBP1 knockdown accelerated the invasiveness of U-87 MG cells 
 
The invasive properties of glioma cell line with and without FUBP1 knockdown 
were investigated. For this purpose, a Boyden chamber transmigration assay was 
performed. Matrigel was layered on the insert and incubated until it became semi-
solid. 4 x 105 cells were seeded on top of the Matrigel in serum-free medium, while 
serum-containing medium was placed in the well below. After 48 hours of 
incubation, crystal violet staining of the membrane exhibited higher numbers of 
FUBP1-deficient U-87 MG cells which had invaded through the pores of the 
transwell membrane, when compared to control cells. LNT-229 FUBP1 knockdown 
cells showed a significantly lower invasive capacity compared to control and U-87 
MG cells lacking FUBP1 (Figure 11).  
 
Results 
 
54 
 
   
 
Figure 11: Influence of the FUBP1 knockdown on cell invasion in LNT-229 and U-87 MG. 
Matrigel was layered on the membrane of the transwell insert and incubated until it became semi-
solid. 3x105 LNT-229 (pSEW vector or pSEW-FUBP1 shRNA transduced (A)) and U-87 MG (pSEW 
vector and pSEW-FUBP1 shRNA transduced (B)) cells were seeded in a serum-free medium on top 
of the Matrigel. The insert was placed in a well with serum-containing medium and incubated for 48 
hours. Later, the membrane was stained with crystal violet, pictures were captured with a microscope 
and invaded cells were counted using ImageJ software. Mean and standard deviation are shown for 
three independent experiments. **: p<0.01, ***: p<0.001.  
 
3.7 FUBP1 knockdown accelerated the closure of a scratch in U-373 MG 
cell monolayer 
 
Because excessive migration is one of the hall marks of glioma cells, a scratch 
wound assay was performed with LNT-229 and U-373 MG cells. 4 x 105 cells were 
seeded in serum-free medium in a well of a 24 well plate. 24 hours later a scratch 
was applied to the cell monolayer using a 1000 µL tip. Cells were washed twice 
with 1X PBS, to remove the dead or floating cells. 24 hours after scratching, 
FUBP1-deficeint LNT-229 cells showed a larger uncovered area (60%; Figure 12 
(A) & (B)) of the scratch, compared to control LNT-229 cells (40%; Figure 12 (A) & 
(B)). However, in FUBP1 knockdown U-373 MG cells, less uncovered area (60%; 
Figure 12 (C) & (D)) was observed compared to control U-373 MG cells (100%; 
Figure 12 (C) & (D)). 
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Figure 12: Influence of the FUBP1 knockdown on the migration potential in LNT-229 and U-
373 MG cells. 
3x105 LNT-229 (pSEW vector or pSEW-FUBP1 shRNA transduced (A)) and U-373 MG (pSEW vector 
or pSEW-FUBP1 shRNA transduced (C)) cells were seeded in serum-free medium in a 24 well plate. 
24 hrs later, a scratch/wound was applied using a 1 mL pipet tip. Cells were washed once with PBS 
to remove the detached cells; the well was filled again with serum-free media; pictures of the scratch 
were captured at 0 hrs time point with a microscope, and the cells were incubated. 24 hrs later, 
pictures were captured again with a microscope, and the area uncovered was measured using 
ImageJ software.  
Results 
 
57 
 
3.8 Differential functional role of FUBP1 is due to the cell type and not 
due to its level of expression in cell lines  
 
To identify the key molecules responsible for the differential role of FUBP1 in 
glioblastoma cells, an Affymatrix gene expression array was performed. The 
analysis revealed that in FUBP1-deficient U-87 MG cells, pro-proliferative genes 
were up-regulated and a number of pro-apoptotic genes were downregulated. In 
FUBP1 knockdown LNT-229 cells, the opposite effect was observed: pro-
proliferative genes were downregulated and pro-apoptotic genes were up-
regulated. Further, ingenuity pathway and cluster analysis of the array data with 
Hep3B, HuH7, LNT-229, U-87 MG and U-373 MG was performed. Cluster analysis 
revealed that the regulation of FUBP1 target genes is comparatively more 
significant by cell type and not by FUBP1 knockdown. Ideally in this cluster 
analysis, all the cell lines in which FUBP1 behaves like an oncogene, i.e. Hep3B 
and HuH7 and the glioblastoma cell line LNT-229, should cluster together and the 
cell lines in which FUBP1 acts in an pro-proliferative and anti-apoptotic fashion, 
the glioblastoma cell lines U-87 MG and U-373 MG, should cluster together. 
However, the U-373 MG cells clustered together with LNT-229 cells, and U-87 MG 
cell line clustered together with Hep3B and HuH7 cells, suggesting that the 
clustering was not based on FUBP1 expression rather on different cell types 
(Figure 13).    
 
Results 
 
58 
 
 
 
Figure 13: Affymetrix microarray analysis of gene expression profiles in FUBP1 depleted 
Hep3B, HuH7, LNT-229, U-87 MG and U-373 MG cell lines. 
RNA was isolated from Hep3B, HuH7, LNT-229, U-87 MG and U-138 MG cells that were stably 
transduced with pSEW empty vector or pSEW-FUBP1 shRNA. cDNA was transcribed, purified, 
labelled, fragmented, hybridised, washed and scanned with a laser. Further, clustering analysis of 
the FUBP1 regulated genes was performed using Ingenuity® software. Data from five knockdown 
cell lines are shown. High expression intensities are represented by red, while low expression 
intensities are represented by green colour. Black indicates medium intensities.  
 
3.9 TGFβ-1, MMP9 and MMP2 influence the fate of FUBP1 in glioblastoma 
cell lines 
 
Based on cellular proliferation and apoptosis, the highly regulated genes in 
Affymetrix array upon FUBP1 knockdown (i.e. EGR1, IGF-II, TGF-1, MMP9, MMP2 
and AKT) were selected and further validated by qRT-PCR in LNT-229, U-138, U-
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87 MG and U-373 MG cells. The analysis confirmed that the mRNA expression of 
TGFβ-1, EGR1, MMP2 and AKT was decreased in FUBP1 knockdown LNT-229 
cells compared to control cells (Figure 14 (A)). However, MMP9 mRNA levels was 
3.5 fold upregulated upon FUBP1 knockdown in LNT-229 cells compared to control 
cells. Surprisingly, TGFβ-1 and MMP2 mRNA expression were elevated in FUBP1-
deficient U-87 MG cells compared to the control cells (Figure 14 (B)). MMP9 mRNA 
levels was decreased (50%) upon FUBP1 knockdown in U-87 MG cells compared 
to control cells. There was a decrease of about 40% in FUBP1 knockdown LNT-
229 cells and about 85% in FUBP1 knockdown U-87 MG cells.  
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Figure 14: FUBP1 knockdown influences the expression of TGFβ-1, MMP9 and MMP2 in LNT-
229 and U-87 MG 
RNA was isolated from LNT-229 (A), U-87 MG (B), U-138 MG (C) and U-373 MG (D) cells that were 
stably transduced with pSEW empty vector or pSEW-FUBP1 shRNA. cDNA was transcribed, and 
quantitative real time PCR was performed using the LightCycler®. Relative mRNA expression levels 
were calculated by the 2-ΔΔct method using three housekeeping genes (GAPDH, HPRT1 and SDHA) 
for normalization. Mean and standard deviation are shown for three independent experiments. 
3.10 MMP2 is highly expressed in U-87 MG cells in contrast to LNT-229 
cells 
 
qRT-PCR results revealed that FUBP1 might have a direct or indirect effect on 
MMP2 mRNA expression and might therefore contribute to the differential role of 
FUBP1 in LNT-229 and U-87 MG cells (Figure 14). For further analysis, MMP2-
specific shRNAs were cloned into the lentiviral expression vector pGIPZ. Lentivirus 
was produced in HEK-293T cells and was used for stable transduction of LNT-229 
Results 
 
61 
 
and U-87 MG cells. In addition to MMP2-specific shRNA, the scrambled shRNA 
was used as a control. A zymographic assay was performed to evaluate the activity 
of MMP2 in LNT-229 and U-87 MG cells. MMP2 expression was analyzed using 
the ImageJ software. The analysis revealed that MMP2-specific shRNA led to a 
significant downregulation of MMP2 protein levels, corresponding to the reduction 
in band intensity in MMP2 knockdown cells (Figure 15 (A)). According to the 
quantification, MMP2 levels were higher in U-87 MG cells compared to LNT-229 
cells (Figure 15 (B)).    
 
 
 
Figure 15: Knockdown of MMP2 expression in the glioblastoma cell lines LNT-229 and U-87 
MG 
(A) LNT-229 and U-87 MG cells were transduced with lentiviral particles containing either empty 
pGIPZ vector or pGIPZ-MMP2 shRNA. Following two passages after transduction, knockdown 
efficiency was tested by zymographic assay. Transduction of MMP2 shRNA led to a strong 
downregulation of the MMP2 protein. (B) MMP2 expression was quantified by measuring the band 
intensity using ImageJ software. 80 µg of each cell lysate were loaded for Western blot analysis. 
Ponseau S staining was used as a loading control. The experiment was performed once. 
 
3.11 MMP2 acts upstream of FUBP1 and inhibits FUBP1 mRNA expression 
in U-87 MG cells 
 
Previous studies suggest that MMP2 had been involved in pro-proliferative 
functions and under certain conditions can also activate the proliferative signalling 
cascade allowing the cells to acquire more metastatic and invasive characteristics. 
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qRT-PCR results reveal that MMP2 might be responsible for the differential role of 
FUBP1 in U-87 MG and LNT-229 cells (Figure 14). In order to collect further 
evidence for this, MMP2 knockdown was performed in U-87 MG cells, and FUBP1 
expression was quantified using the FUSION system. The analysis revealed that 
FUBP1 protein expression was increased by two fold upon MMP2 knockdown 
(Figure 16). This observation led us to the assumption that MMP2 acts upstream 
of FUBP1 and might have an important role in regulating the expression of FUBP1 
in U-87 MG cells. Whether, the inhibition of FUBP1 by MMP2 is of a direct or 
indirect effect is still unclear. 
 
 
 
Figure 16: MMP2 knockdown increases FUBP1 protien expression by two fold in U-87 MG 
cells 
(A) U-87 MG cells were transduced with lentiviral particles containing either empty pGIPZ vector, 
pGIPZ-FUBP1 shRNA or pGIPZ-MMP2 shRNA. Following two passages after transduction, FUBP1 
expression was tested by western blotting using an antibody against FUBP1. (B) FUBP1 expression 
was quantified by measuring the band intensity using the FUSION software. 80 µg of each cell lysate 
were loaded for western blot analysis. β-Actin was used as a loading control. 
 
3.12 FUBP1 knockdown increases MMP2 levels and simultaneously 
inhibits MMP9 in U-87 MG-like glioblastoma cells 
 
Western blot results (Figure 16 (A)) revealed that the knockdown of MMP2 
increases FUBP1 levels in U-87 MG cells. I was interested to test the effect of a 
FUBP1 knockdown on MMP2 activity in further glioblastoma cell lines. LNT-229, 
U-138 MG, U-87 MG and U-373 MG cells were stably transduced with empty 
pSEW vector and pSEW-sh2FUBP1. Cells were analyzed for FUBP1 expression 
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(Figure 7 (A, B, C)) and a zymographic gel was prepared and run to quantify the 
activity of MMP2 and MMP9. LNT-229 and U-138 MG cells showed a decrease in 
MMP2 activity and an increase in MMP9 activity upon FUBP1 knockdown (Figure 
17 (A)). FUBP1-deficient U87-MG and U-373 MG cells showed the opposite effect, 
i.e. an increase in MMP2 activity and a decrease in MMP9 activity (Figure 17 (B)). 
These results correlated with the findings obtained by qRT-PCR (Figure 14 (A, B, 
C, D)). 
 
 
  
    
Figure 17: Influence of a FUBP1 Knockdown on MMP2 & MMP9 expression in the glioblastoma 
cell lines LNT-229, U-138 MG, U-373 MG and U-87 MG 
(A) LNT-229 and U-87 MG cells were transduced with lentiviral particles containing either empty 
pGIPZ vector or pGIPZ-FUBP1 shRNA. Following two passages after transduction, MMP2 activity 
was tested by a zymographic assay. Transduction of FUBP1 shRNA led to a strong downregulation 
of MMP2 activity and an increase in MMP9 activity in LNT-229 and U-138 MG cells (A & B). In FUBP1 
knockdown U-87 MG and U-373 MG cells, MMP2 levels were upregulated and MMP9 levels were 
downregulated (A and B). 80 µg of each cell lysate were loaded for Western blot analysis. Ponseau 
S staining was used as a loading control. 
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3.13 The AKT1 pathway is activated in U-87 MG cells and might be 
responsible for pro-proliferative properties upon FUBP1 knockdown 
 
qRT-PCR data suggest that the FUBP1 knockdown decreases AKT1 mRNA levels 
in LNT-229 and U-87 MG cells. However, AKT1 was still highly expressed in 
FUBP1 knockdown U-87 MG cells compared to LNT-229 cells (Figure 14 (A) & 
(B)). Further, I investigated the expression of AKT and that of other molecules 
involved in the AKT pathway in LNT-229 and U-87 MG cells with respect to FUBP1 
knockdown. Western blot results revealed that AKT pathway members i.e. PDK1, 
AKT, p-AKT (T308), p-AKT (s473) and p-GSK3β (s9) are active (phosphorylation 
of (a) tyrosine at 308 and serine at 473 in p-AKT (b) serine at 9 in p-GSK3β) and 
show reasonable/moderate expression in U-87 MG cells compared to LNT-229 
cells (Figure 18). However, no significant difference between control U-87 MG cells 
and FUBP1-deficient U-87 MG cells could be detected in PDK1, AKT, p-AKT 
(T308), p-AKT (s473) and p-GSK3β (s9).  
 
 
Figure 18: FUBP1 knockdown influences AKT and that of other molecules involved in the AKT 
pathway expression in the glioblastoma cell line U-87 MG 
LNT-229 and U-87 MG cells were transduced with lentiviral particles containing either empty pSEW 
vector (Control) or pSEW-FUBP1 shRNA (FUBP1 k.d.). Two passages after transduction, the 
expression of PDK1, AKT, p-AKT (T308), p-AKT (s473) and p-GSK3β (s9) was tested by 
immunoblotting with the appropriate specific antibodies. 80 µg of each cell lysate was loaded for 
Western blot analysis. β-Actin was visualized as a loading control. 
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3.14 Consequences of FUBP1 knockdown in glioblastoma cell lines in a 
mouse xenograft transplantation tumour model 
 
The in vitro data above suggests a functional relevance for the role of FUBP1 as 
an oncogene in glioblastoma. To verify this hypothesis, LNT-229 and U-87 MG 
cells stably transduced with empty pSEW vector or pSEW-shFUBP1 were injected 
into the flanks of immunocompromised NOD/SCID mice. Tumor growth was 
monitored over a period of four weeks.  
U-87 MG FUBP1-deficient tumors grew significantly faster than control tumors 
(Figure 19 (B)). Interestingly, LNT-229 FUBP1 knockdown tumors expanded 
slower than control tumors (Figure 19 (A)). These findings confirmed that FUBP1 
expression is required for tumor growth in LNT-229 cells and they support the 
cellculture data described above. The experiment with U-87 MG cells was 
performed by Dr. Bettina Schwamb, group of Prof. Dr. Martin Zörnig, Georg-
Speyer-Haus, Frankfurt. 
 
 
 
Figure 19: FUBP1 knockdown reduces/promotes tumor growth of LNT-229/U-87 MG cells in a 
xenograft transplantation model 
7x106 stably transduced LNT-229 (A) and U-87 MG (B) cells were subcutaneously injected into the 
flanks of 5-6 weeks old immunodeficient NOD-SCID mice. Tumor volume was measured using 
callipers. 10 mice were used for each group. Data is presented as median ± standard error. On day 
59 for LNT-229 and on day 35 for U-87 MG there has been significant difference. 
**: p<0.01, ***: p<0.001.  
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3.15 Overexpression of FUBP1 in Hep3B cells 
 
Previous studies revealed that silencing FUBP1 mRNA expression reduced 
tumour growth in Hep3B cells and that FUBP1 might represent a therapeutic target 
for HCC. We wanted to test whether FUBP1 can be further overexpressed in 
Hep3B cells. In order to achieve that, Hep3B cells were infected with FLAG-tagged 
adenoviral vector. From the western blot and qRT-PCR results (Figure 20), we 
concluded that upon adenoviral infection with FUBP1 cDNA vectors, FUBP1 
mRNA levels were significantly increased but not FUBP1 protein levels. This led 
us to hypothesize and investigate whether miRNAs might play an important role in 
repressing the expression of FUBP1.   
 
 
Figure 20: Overexpression and Down-regulation of endogenous FUBP1 levels in Hep3B cells  
(A) Hep3B cells were infected with adenoviral particles containing either control Ad-GFP, FLAG 
tagged Ad-FLAG-FUBP1, empty pSEW vector or pSEW-FUBP1 shRNA. Following two 
passages after infection, knockdown and overexpression efficiencies were tested by 
immunoblotting with a FUBP1-specific antibody. Transduction of FUBP1 shRNA led to a 
strong downregulation of FUBP1 protein levels. However, no FUBP1 overexpression was 
detected in Ad-FLAG-FUBP1-transduced Hep3B cells. β-actin was used as a loading 
control. (B) qRT-PCR analysis confirmed that the FUBP1 mRNA levels were significantly 
reduced in FUBP1 shRNA-transduced Hep3B cells compared with the empty vector-
transduced cells (pSEW). Surprisingly, there was a significant overexpression of FUBP1 
mRNA levels in Hep3B cells transduced with Ad-FLAG-FUBP1.  
*The experiment was performed once. n=1 
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3.16 Effect of FUBP1 knockdown on miRNA regulation in Hep3B cells 
 
To investigate whether FUBP1 regulates miRNA expression in HCCs, a custom-
made miRNA array kit (Carlo Croce’s lab, The Ohio state University, USA) was 
hybridized to identify miRNAs deregulated in Hep3B cells. The expression of 
different miRNAs in pSEW-shFUBP1 and empty pSEW -transduced Hep3B cells 
was compared. The analysis of the miRNA array data led to the identification of 62 
differentially regulated miRNAs in Hep3B cells. The majority of miRNAs affected 
by the FUBP1 knockdown were down-regulated in Hep3B cells, and according to 
the literature, several miRNAs implicated in the development of a variety of tumor 
entities. Based on the literature survey and their relevance to HCC, 14 miRNAs 
were selected for further analysis (Table 32). The data obtained with FUBP1 
knockdown Hep3B cells were further analysed.  
 
Table 32: miRNAs which have been related to HCC and which are differentially expressed 
upon FUBP1 knockdown  
miRNA 
hsa-miR-1 
has-miR-15a 
hsa-miR-17 
hsa-miR-21 
hsa-miR-23a 
hsa-miR-26a 
hsa-miR-30d 
hsa-miR-100 
hsa-miR-146a 
hsa-miR-199b 
hsa-miR-219 
hsa-miR-330 
hsa-miR-422a 
hsa-miR-613 
hsa-miR-495 
 
3.17 Prediction of miRNA binding sites located in the 3’UTR of the FUBP1 
gene 
 
 As endogenous expression of FUBP1 appears under strict transcriptional control 
(Figure 20), FUBP1 overexpression is not achieved upon transfection/transduction 
of FUBP1 cDNA. We hypothesised that miRNAs might play an important role in 
regulating the expression of FUBP1. Further, we were interested in looking for a 
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feedback loop mechanism by a particular miRNA which would repress FUBP1 
protein. Using the Target Scan miRNA target prediction tool, I discovered 8 
miRNAs (miR1, miR26a, miR613, miR21, miR199b, miR15a, miR17, miR26a and 
miR495) which might regulate FUBP1 by binding to the 3’UTR of the FUBP1 gene 
(Figure 21).  
 
 
 
miRNA Seed Region(s) 
(Nucleotide No.) 
has-miR-495  51-57, 92-101, 208-215 
has-miR-26a 76-82, 742-749 
has-miR-199b 60-70 
has-miR-613 237-245 
has-miR-1 240-245 
has-miR-17 292-297, 313-319 
has-miR-21 447-454 
has-miR-15a 701-708 
 
Figure 21: Eight miRNAs are predicted to bind to the 3’UTR of the FUBP1 gene 
The Prediction was performed using miRanda software (http://www.microrna.org/). Only miRNAs 
that were deregulated in the absence of FUBP1 are shown. miR-26a has two and miR-495 has three 
potential binding sites, respectively.  
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3.18 Potential regulation of FUBP1 levels by miRNA binding in the 3’UTR 
region of FUBP1 in Hep3B cells 
 
To test whether miRNAs repress FUBP1 mRNA expression, the FUBP1 3′ UTR 
was cloned into the 3′ UTR region of a luciferase reporter vector downstream of 
the firefly luciferase gene. The constitutively active Renilla reporter was co-
transfected with the luciferase reporter vector containing either the wild type 
FUBP1 3’UTR or the FUBP1 3’UTR with mutated miRNA binding sites into Hep3B 
cells. Transfection of the FUBP1 3′UTR luciferase reporter with mutated miRNA 
binding sites resulted in increased luciferase activity for certain miRNAs (Figure 
22) suggesting that certain miRNAs might repress FUBP1 expression upon binding 
to its 3′ UTR. Mutated binding sites for miR-17, miR-15, miR-21, miR-26 and miR-
495 showed an increase in luciferase activity and might be responsible for 
repressing FUBP1 expression in Hep3B cells. The constructs miR-26-I, miR-495 
3X (triple mutant) and miR-21 showed a three-fold increase in luciferase activity 
compared to wildtype FUBP1 3’UTR (Figure 22). For miR-26, the FUBP1 3’UTR 
contains two and for miR-495 three potential binding sites, but only one single 
mutant of the miR-26 binding site (i.e. miR-26-I), one double mutant of the miR-
495 binding site (miR-495-I+II), and the triple mutant (miR-495 3X) of the miR-495 
binding site showed increased luciferase activity (Figure 22). 
   
 
Figure 22: miRNAs regulating FUBP1 by binding to its 3’UTR 
Hep3B cells were cultured in 24-well plates. 24 hrs later, they were co-transfected with wild type or 
mutated FUBP1 3’UTR plasmids, Renilla normalization plasmid (pGL 4.74) and pcDNA using 
Attractene (QIAGEN, Hilden, Germany). The Renilla normalization plasmid was used to transfect 
equal amounts of DNA into the cells. Luciferase activity was measured 48 hours post transfection 
using the Dual-luciferase reporter assay system (Promega).  
*The experiment was performed once in triplicates. n=1 
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4.1 FUBP1 downregulation in glioblastoma cells regulates apoptosis and 
proliferation 
 
As a cell culture system for the functional analysis of FUBP1 in glioblastoma cells, 
the glioblastoma cell lines LNT-229, SKMG-3, LN-428, U-138 MG, U-87 MG and 
U-373 MG were chosen, and lentiviral shRNA expression was used as a tool for 
the manipulation of FUBP1 activity. Downregulation of FUBP1 expression was 
achieved by transduction of the cells with a lentiviral pSEW vector construct 
expressing a shRNA that specifically targets the FUBP1 mRNA. Upon identification 
of FUBP1 in a screen for anti-apoptotic genes and confirmation of the anti-
apoptotic potential in the hepatocellular carcinoma cell line Hep3B, we could 
demonstrate an oncogenic function for FUBP1 in HCCs (Rabenhorst, 
Beinoraviciute-Kellner et al. 2009). Moreover, our group detected a low expression 
of FUBP1 in astrocytes and demonstrated elevated levels of FUBP1 in 
glioblastoma, the most common malignant brain tumor in humans. In addition, Prof. 
Kinzler’s laboratory found that inactivating mutations in the genes CIC and FUBP1 
contribute to human oligodendroglioma (Bettegowda, Agrawal et al. 2011). 
Thus, we suspected that the inhibition of FUBP1 might facilitate a curative gateway 
for glioblastoma. Therefore, the effect of FUBP1 downregulation on apoptosis 
sensitivity and proliferation of glioblastoma cell lines was tested. Before 
quantification of apoptosis, cells were treated with MG-132 (a proteosomal 
inhibitor) and recombinant TRAIL and they were incubated for 5-6 hours to induce 
apoptosis. Knockdown of FUBP1 in the glioblastoma cell lines LNT-229, SKMG-3, 
LN-428 and U-138 MG led to a significantly increased rate of spontaneous 
apoptosis relative to control cells (Figure 8). Surprisingly, the FUBP1-deficient 
glioblastoma cell lines U-87 MG and U-373 MG were resistant to apoptotic stimuli 
and showed significant reduced apoptosis compared to control cells with normal 
FUBP1 expression levels. 
 
TRAIL, a member of the tumor necrosis factor/death receptor (DR) gene 
superfamily can bind to 4 plasma membrane receptors and 1 soluble receptor, that 
is, TRAIL-R1 (DR4), TRAIL-R2 (DR5/ KILLER), TRAIL-R3 [decoy receptor (DcR) 
4. Discussion 
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1], TRAILR4 (DcR2), and osteoprotegerin (Kelley and Ashkenazi 2004). 
Oligomerisation of the DcR4 and DcR5 receptors leads to formation of the death-
inducing signaling complex (DISC), which recruits the adaptor molecule, FADD, 
and activates Caspase-8 and -10. These activated caspases cleave and activate 
Caspase-3, which in turn cleaves substrates that commit cells to undergo 
apoptosis (Wang and El-Deiry 2003). TRAIL resistance may result from a 
combination of increased AKT activity (Puduvalli, Sampath et al. 2005) and 
deficient expression of caspases. Therefore, based on the cell type, FUBP1 
downregulation increases sensitivity of the cells to apoptosis, and FUBP1 
overexpression in glioblastoma cell lines might contribute to tumor formation by 
inhibition of cell death. 
 
Previously, it was published that FUBP1 expression is required for the proliferation 
of leukemia (He, Weber et al. 2000) and Hep3B cells (Rabenhorst, Beinoraviciute-
Kellner et al. 2009). Activation of c-myc expression might be expected in other cell 
types as well. Stimulation of cell proliferation could provide another mechanism by 
which FUBP1 overexpression contributes to the formation of glioblastoma. Cell 
proliferation was measured by EdU (5-ethynyl-2’-deoxyuridine) labelling. Stable 
transduction with pSEW-sh2 FUBP1 shRNA led to a decreased percentage of 
EdU-positive cells compared to control cells in the LNT-229, SKMG-3, LN-428 and 
U-138 MG cell lines (Figure 9). Thus, less cells were in S-phase during the EdU 
incubation period. But surprisingly, FUBP1-deficient U-87 MG and U-373 MG cells 
showed an increased percentage of EdU-positive cells compared to control cell 
(Figure 9). Collectively, the result confirm that downregulation of FUBP1 leads to 
reduced proliferation of glioblastoma cells (LNT-229, SKMG-3, LN-428 and U-138 
MG). However, in U-87 MG and U-373 MG cells, FUBP1 might fullfill a special 
important function relavant for glioblastomas which differs from its role in HCC. 
  
The in vitro assays demonstrated that FUBP1 overexpression inhibits apoptosis 
and stimulates proliferation in most glioblastoma cell lines (LNT-229, SKMG-3, LN-
428 and U-138 MG), implying an oncogenic function for FUBP1 in glioblastoma. 
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4.2 TGFβ-1 and MMP9 regulate FUBP1 expression in glioblastoma cell 
lines 
 
To test the differential role of FUBP1 in different glioblastoma cell lines, an 
affymetrix array was performed. Analysis of the array revealed a set of genes which 
were regulated upon FUBP1 knockdown (Figure 13). Further qRT-PCR analysis 
confirmed four genes (i.e. TGFβ-1, MMP9, MMP2 and AKT1) that were highly 
regulated upon FUBP1 knockdown (Figure 14). The above-mentioned genes were 
selected for further analysis based on their involvement in cellular functions like 
proliferation, apoptosis, migration and invasion in glioblastoma.  
 
In FUBP1-deficient LNT-229 cells, the mRNA levels of TGFβ-1, MMP2 and AKT1 
were downregulated compared to control cells. The levels of MMP9 were highly 
elevated in FUBP1-deficient LNT-229 cells compared to control cells. In contrast 
to LNT-229 cells, FUBP1 knockdown U-87 MG cells showed increased TGFβ-1, 
MMP2 and AKT1 mRNA levels and decreased MMP9 mRNA levels compared to 
control cells.  
 
Angiogenesis is a fundamental process during which new blood vessels are 
formed (Folkman and Shing 1992, Risau 1997). Highly regulated and transient 
angiogenesis plays a pivotal role in development, morphogenesis, wound repair, 
and reproduction (Folkman and Shing 1992, Salamonsen 1994, Risau 1997). 
Angiogenesis is mainly associated with extracellular remodelling involving different 
proteolytic systems among which the plasminogen system plays an important role. 
Plasmin is an important enzyme which degrades many blood plasma proteins 
including fibrin. It is highly expressed in human brain and blood. MMP7 and MMP9 
convert human plasminogen to angiostatin fragments (Patterson and Sang 1997). 
Angiostatin (a fragment of plasminogen) and endostatin (a fragment of type XVIII 
collagen) are examples of endogenous inhibitors of angiogenesis (O'Reilly, 
Holmgren et al. 1994, O'Reilly 1997). Basing on these results we hypothesize that 
in FUBP1-deficient LNT-229 cells, increased MMP9 mRNA levels lead to the 
formation of angiostatin by degrading plasminogen. As a result, reduced cell 
proliferation was observed. Similarly, in FUBP1 knockdown U-87 MG cells, 
decreased MMP9 mRNA levels lead to a malfunction in the production of 
angiostatin. As a result, there was an increase in cell proliferation and vascular 
tube formation capacity.    
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Transforming growth factor (TGF) - β is a member of a structurally related family 
of secreted growth factors, which also includes activins and bone morphogenetic 
proteins (BMPs). TGF-β superfamily members induce many of the biological 
effects in a context-dependent manner and have been shown to regulate 
proliferation, differentiation, migration, and apoptosis of many different cell types 
(Massague 1990, Roberts, Heine et al. 1990). In many cases, cellular perturbations 
of protein translocation have been reported to lead to alterations in gene 
expression that in turn leads to disease development (Dreger 2003, Bennett 2005). 
TGFβ-1 regulates FUBP1 localisation (Milosevic, Bulau et al. 2009). In addition, 
TGFβ induces p38 MAP kinase phosphorylation and nuclear translocation. 
Therefore, we speculate that, FUBP1 translocation might be regulated by p38 
MAPK activity, as p38 is required for the regulation of FUSE-binding protein and 
c-myc expression. So, the increase in TGFβ-1 mRNA levels in FUBP1-deficient U-
87 MG cells might be via p38 MAPK signalling. Studies in our lab showed that 
FUBP1 is exclusively localised in the nucleus of HCC cells (data not shown). 
Hence, in FUBP1-deficient U-87 MG cells, there is an increase in TGFβ-1 mRNA 
levels which further excises it’s pro-proliferative and angiogenic functions.         
 
 
 
 
 
 
 
 
Figure 23: Translocation of FUBP1 after TGFβ-1 stimulation 
A549 lung epithelial cells were stimulated with TGFβ-1 (2ng/mL) for the indicated time points. 
Cytosolic and nuclear fraction were prepared and western blotting was performed (Milosevic, Bulau 
et al. 2009).  
4.3 FUBP1 expression regulates proliferation, migration and invasion in 
glioblastoma cell lines via MMP2 
 
From our qRT-PCR results we know that MMP2 might be an important candidate 
for explaining the differential role of FUBP1 in glioblastoma cell lines. In FUBP1-
deficient U-87 MG cells, there is an increase in MMP2 mRNA levels compared to 
control cells. But in FUBP1 knockdown LNT-229 cells, there is a decrease in MMP2 
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mRNA levels compared to control cells. Matrix metalloproteinases (MMPs) are a 
family of calcium-dependent zinc-containing endopeptidases, which are 
responsible for the tissue remodelling and degradation of the extracellular matrix 
(ECM). Degradation of the ECM by MMPs not only enhances tumour invasion, but 
also affects tumour cell behaviour and leads to cancer progression. Most human 
MMPs can be grouped into four main subclasses on the basis of substrate 
specificity, protein-domain structure and sequence homology (Shingleton, Hodges 
et al. 1996). Studies suggest strong correlations between increased MMP levels 
and tumour-cell invasion in human gliomas. MMPs enhance tumour-cell invasion 
by degrading extracellular- matrix proteins, activating signalling cascades that 
promote motility and solubilizing ECM-bound growth factors (McCawley and 
Matrisian 2001). In addition, MMPs can cleave and activate growth factors that are 
implicated in glioblastoma motility and proliferation, such as TGFβ (Platten, Wick 
et al. 2001). TGFβ-1 up-regulates these MMPs in cultured human keratinocytes 
(Salo, Lyons et al. 1991) and human fibroblasts (Overall, Wrana et al. 1991). 
Rooprai et al. have showed in their study that in glioma cells MMP2 expression is 
directly related to TGFβ1 levels. There is a significant increase in MMP2 levels 
when induced with TGFβ-1 (Figure 24).    
    
Figure 24: Zymogram gel representing MMP2 expression when induced with growth factors 
A zymographic assay was performed using the glioma cell line IPAB-AO3, to investigate the effect of 
various growth factors on MMP2 expression. The intense band at 72 kDa represents MMP2, and the 
less intense band at 92 kDa represents MMP9 (Rooprai, Rucklidge et al. 2000).    
 
To test whether MMP2 has a potential role in executing the pro-proliferative, pro-
angiogenic functions of FUBP1 and whether it is involved in regulating the 
expression of FUBP1 in U-87 cells, a zymographic assay was performed. The 
zymogram gel revealed that the activity of MMP2 is higher in U-87 MG cells 
compared to LNT-229 cells, which correlated with the qRT-PCR data. To test the 
effect of FUBP1 knockdown on the cellular invasion and migration potential, a 
matrigel invasion assay and a scratch wound assay were performed. In both 
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assays, FUBP1-deficient U-87 MG cells invaded and migrated more intensively 
compared to control cells. However, in LNT-229 cells, FUBP1 knockdown cells 
showed a lower invasion and migration capacity compared to control cells (Figure 
11, Figure 12).  
 
In addition, the vascular tube formation capacity of the glioblastoma cell lines (LNT-
229 and U-87 MG) in the presence and absence of FUBP1 was investigated. 
FUBP1-deficient LNT-229 cells failed to form tubular-like structures compared to 
control cells, whereas FUBP1 knockdown U-87 MG cells formed clean tubular-like 
structures (Figure 10). The increase in MMP2 levels in the FUBP1-deficeint U-87 
MG cells may be the reason for the elevated proliferation, migration and invasion.              
4.4 A potential feedback loop exists between FUBP1 and MMP2 
From the zymographic assay it was evident that the MMP2 activity was higher in 
U-87 MG cells compared to LNT-229 cells (Figure 15). In order to test and reverse 
the FUBP1 knockdown phenotype in U-87 MG cells, MMP2 activity was inhibited 
using a shRNA targeting MMP2. Surprisingly, FUBP1 protein levels were 
increased two-fold upon MMP2 knockdown in U-87 MG cells (Figure 16). 
Interestingly, there was no difference observed in FUBP1 protein levels in MMP2-
deficient LNT-229 cells compared to control LNT-229 cells. Furthermore, MMP2 
and MMP9 levels were investigated upon FUBP1 knockdown in U-87 MG cells. 
FUBP1-deficient U-87 MG cells showed a higher MMP2 activity and a lower MMP9 
activity compared to control U-87 MG cells (Figure 17), on the other hand, FUBP1 
knockdown LNT-229 and U-138 MG cells showed a higher MMP9 activity and 
lower MMP2 activity compared to control cells. These results strongly suggest that 
there is a feedback loop mechanism between FUBP1 and MMP2 in U-87 MG cells 
which might also contribute to the differential role of FUBP1 in U-87 MG and LNT-
229 cells.     
 
The results showed an increase in MMP2 levels both on mRNA and protein levels 
upon FUBP1 knockdown in U-87 MG cells, which might represent an important 
factor for the increased proliferation, invasion, migration and the decreased 
apoptosis sensitivity of FUBP1-deficient U-87 MG cells. To reverse the phenotype, 
simultaneous knockdown of MMP2 and FUBP1 was performed in U-87 MG cells, 
and functional assays were investigated. Apoptosis assays revealed that a 
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MMP2/FUBP1 double knockdown in U-87 MG cells showed higher apoptotic rates 
compared to control and FUBP1 single knockdown U-87 MG cells.           
4.5 AKT1 signalling is active in U-87 MG cells but completely absent in 
LNT-229 cells 
 
From qRT-PCR results we know that AKT1 might be one important candidate to 
explain the differential role of FUBP1 in glioblastoma cell lines. In FUBP1-deficient 
U-87 MG cells, higher AKT1 mRNA levels were observed compared to FUBP1-
deficient LNT-229 cells. However, in FUBP1 knockdown LNT-229 cells, AKT1 
mRNA levels were lower than in control cells and FUBP1-deficient U-87 MG cells. 
From the apoptosis assays, we could conclude that FUBP1 knockdown U-87 MG 
cells were highly resistance to TRAIL and MG132. TRAIL resistance may result 
from a combination of increased AKT1 activity (Puduvalli, Sampath et al. 2005) 
and deficient expression of caspases. In order to test the involvement of AKT1 and 
its pathway members in the regulation of FUBP1 in different glioblastoma cell lines, 
we investigated the AKT-pathway in the presence and absence of FUBP1. Results 
revealed that the AKT-pathway was completely silent in LNT-229 cells, whereas in 
U-87 MG cells, the AKT1-pathway was active. As LNT-229 cells express a wildtype 
PTEN, this might be the reason for the shutdown of AKT-pathway. Since U-87 MG 
cells harbor mutant PTEN, this would inhibit the formation of PDK1 and the 
downstream members of AKT-pathway.         
4.6 FUBP1 overexpression is required for tumor growth in LNT-229 cells 
 
To test whether FUBP1 is of functional importance for the formation of solid tumors 
in vivo, LNT-229 and U-87 MG cells transduced with scrambled lentiviral pSEW 
vector or the shRNA construct pSEW-sh2 FUBP1 were subcutaneously injected 
into the flanks of immunodeficient NOD/SCID mice, and tumor growth was 
monitored. While tumors formed by LNT-229 control cells expanded to a volume 
of 1 cm3 within 65 days, tumors initiated by injection of FUBP1-deficient LNT-229 
cells only grew to a size of about 650 mm3 during the same time (Figure 19 (A)). 
Surprisingly, tumors formed by FUBP1-deficient U-87 MG cells expanded to a 
volume of 600 mm3 within 35 days compared to U-87 MG control cells which 
formed tumors of a volume of 150 mm3 during the same time period (Figure 19 
(B)).  
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According to these results, downregulation of FUBP1 in the glioblastoma cell line 
LNT-229 reduces tumor cell expansion, while the same knockdown enhances 
expansion in U-87 MG cells in a xenograft mouse model as would have been 
predicted from the functional cell culture assays. Taken together, these results 
confirm that FUBP1 overexpression is required for growth of tumors formed by the 
glioblastoma cell line LNT-229 in vivo. Prof. Michal Mittelborn (Edinger Institute, 
Frankfurt) in his laboratory checked for mutational status of FUBP1 in glioblastoma 
cell line and primary glioblastomas. There were no mutations found in either of 
them (Personal Communication). This led us to conclude that in U-87 MG cells, 
FUBP1 might fulfill a special important function which differs from its role in LNT-
229 cells.     
 
Based on my results obtained in different glioblastoma cell lines, I conclude that 
FUBP1 executes its function depending on the cell line. Looking at the observed 
effects of TGFβ-1, MMP9 and MMP2, we put forward the following scheme to 
explain the molecular function of FUBP1 in different glioblastoma cell lines. In LNT-
229 cells, upon FUBP1 knockdown TGFβ-1 expression is reduced, which results 
in decreased MMP2 downstream activity and less cell proliferation, migration and 
tumor growth, while the apoptosis sensitivity in the cell is increased in the absence 
of FUBP1. However, in FUBP1-deficient U-87 MG cells there is increased TGFβ-
1 expression which enhances MMP2 downstream activity, leading to increased 
proliferation, migration, enhanced tumor growth and reduced apoptosis sensitivity.      
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